

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K		A2	(11) International Publication Number: WO 00/09537
			(43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/US99/17867		[US/US]; 4607 Cypress Wood Drive, Spring, TX 77379 (US).	
(22) International Filing Date: 6 August 1999 (06.08.99)		(74) Agents: EISENSTEIN, Ronald, I. et al.; Nixon Peabody LLP, 101 Federal Street, Boston, MA 02110 (US).	
(30) Priority Data: 60/096,795 14 August 1998 (14.08.98) US 60/129,806 16 April 1999 (16.04.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US Not furnished (CIP) Filed on Not furnished		Published Without international search report and to be republished upon receipt of that report.	
(71) Applicant (for all designated States except US): ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; Tulane University Medical Center, School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112-2699 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BOWERS, Cyril, Y. [US/US]; 484 Audubon Street, New Orleans, LA 70118 (US). MOMANY, Frank [US/US]; Versailles Hamlet #816, 935 Loire Court, Peoria, IL 61614 (US). LIANG, Yongwu			
(54) Title: COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY			
(57) Abstract Compounds that promote growth hormone releasing activity are disclosed. These compounds have the formula: A ₁ -A ₂ -X; A ₁ -X', or A ₁ -Y. These compounds can be present in a pharmaceutical composition. The compounds can be used with a second compound that acts as an agonist at the growth hormone releasing hormone receptor or which inhibits the effects of somatostatin. These compounds can be used for a variety of uses such as treating hypothalamic pituitary dwarfism, osteoporosis, burns, or promoting wound healing.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LR	Liberia	SD	Sudan		
DK	Denmark			SE	Sweden		
EE	Estonia			SG	Singapore		

- 1 -

COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY

FIELD OF THE INVENTION

This invention relates to novel compounds that promote the release of growth hormones when introduced to animals, preferably humans, and methods of use thereof.

5

BACKGROUND OF THE INVENTION

The elevation of growth hormone (GH) levels in animals, e.g., mammals including humans, upon administration of GH-releasing compounds can lead to enhanced body weight and to enhanced milk production if sufficiently elevated GH levels occur upon administration. Further, it is known that the elevation of growth hormone levels in mammals and humans can be accomplished by application of known growth hormone releasing agents, such as the naturally occurring growth hormone releasing hormones.

15 The elevation of growth hormone levels in mammals can also be accomplished by application of growth hormone releasing peptides (GHRPs), some of which have been previously described, for example, in U.S. 4,223,019; U.S. 4,223,020; U.S. 4,223,021; U.S. 4,224,316; U.S. 4,226,857; U.S. 4,228,155; U.S. 4,228,156; U.S. 4,228,157; U.S. 4,228,158; U.S. 4,410,512; U.S. 4,410,513.

20 Antibodies to the endogenous growth hormone release inhibitor, somatostatin (SRIF) have also been used to cause elevated GH levels. In this latter example, growth hormone levels are elevated by removing the endogenous GH-release inhibitor (SRIF) before it reaches the pituitary, where it inhibits the release of GH.

25

These methods for promoting the elevation of growth hormone levels frequently involve materials which are expensive to synthesize and/or difficult to isolate in sufficient purity for administration to a target animal. Low molecular weight, relatively simple and inexpensive compounds that

- 2 -

have the ability to promote the release of growth hormone would be desirable in that they could be readily and inexpensively prepared, easily modified chemically and/or physically, as well as easily purified and formulated, and designed to have improved transport properties.

5 GH and/or GHRPs have been administered to stimulate growth hormone production and/or release, for example, to stimulate growth, enhance milk production, enhance body weight, increase rate of protein synthesis, reduce rate of carbohydrate utilization, increase mobilization of pre-fatty acids. Although the use of many of these compounds such as a
10 series of short peptides (e.g., U.S. Patent Nos. 5,663,146 and 5,486,505) have been important steps in the design and delivery of compounds having GH and/or GHRP properties, improvements can still be made. For example, improvements can be made in the areas of oral bioavailability, serum retention time, etc.

15 Non-peptidal or hybrid-peptidal secretagogues have also been described. See U.S. Patent Nos. 5,494,919; 5,492,920; 5,492,916; 5,622,973; WO95/13069, WO96/15148; WO96/35713; WO97/22367; WO97/00894; WO97/07117; and WO97/11697. Despite the general descriptions of such compounds, it is not possible to make broad
20 generalizations about which particular compounds are favorable. Although some secretagogues, which can promote the release and elevation of growth hormone levels in the blood, have been described, corresponding data on the biological activity has often been lacking. Moreover, even in terms of tripeptides with or without C-terminal modifications, the data suggests that
25 it has heretofore been impossible to make the broad sweeping generalization made in those publications about what would or would not be a favorable amino acid combination at the three positions of a tripeptide holding the C-terminal constant or holding the peptidal portion constant while making changes, or changing the chemical moieties added. Changes in any of the
30 constituents can have great effects on activity. It is submitted that these references do not lead to general teachings of biological efficacy.

In order to maximize the ability to select and tailor a compound, it would be desirable to have a class of compounds that generally provide good growth hormone releasing effects and have at least one other desirable

- 3 -

biological activity such as better bioavailability, absorption, metabolism, pharmacokinetics, excretions, etc. It would also be desirable to have compounds which can promote the release and elevation of growth hormone levels in the blood of animals, particularly in humans, to be able to use such compounds to promote the release and/or elevation of growth hormone levels in the blood of animals and humans, and to provide methods for promoting the release and/or elevation of growth hormone levels in the blood of animals using such compounds.

The aforementioned discussion illustrates that a broad chemical diversity of synthetic GHRPs ranging from peptides to partial peptides to non-peptides. Overall, the peptides and partial peptides have been the most effective in promoting elevated growth hormone levels. For example, partial peptides consisting of natural and unnatural amino acids of different chain lengths and C-terminal amide groups or a substituted amide with various organic chemical groups. Results published as early as 1982 stated that certain GHRPs with only 3-7 amino acids released GH and that having a D-amino acid at certain positions was useful. From 1982 to the present, GHRPs with more potent GH releasing activity have been developed. This research taught that certain amino acid positions could have certain substitutions but not others, and that one amino acid residue could affect what other substitutions could be made.

Until compounds having the optimum physical-chemical properties and physiological-biological actions and effects are discovered for various diagnostic and therapeutic uses in humans, it is important to discover a general chemical approach that will result in new types of GHRPs. Such a broader GHRP chemical base will make it possible to better implement and refine the GHRP approach.

Properties of GHRPs that are important include that they are effective when administered orally. In addition, the compound should augment the normal pulsatile physiological secretion of GH. In some subjects with decreased GH secretion, GH can be replaced in a physiological way. Physiological replacement of a hormonal deficiency improves health while minimizing the potential adverse action of the hormone. This is especially important in treating older men and women, as they may be particularly

- 4 -

susceptible to the adverse effects of over-treatment with GH. Already, chronic administration of GHRPs to animals and humans has produced anabolic effects. Body weight gain has been increased in rats, milk production has been increased in cows. Additionally, when a compound
5 such as DAla-D β Nal-Ala-Trp-DPhe-Lys-NH₂ (GHRP-2) was administered to short-statured children with various degrees of GH deficiency 2-3 times per day over a 2 year period, the rate of height velocity has been accelerated in those children.

In principle, the anabolic biological effects of GHRPs emphasize the
10 potential clinical value of the GHRP approach. The finding that GHRP-2 is less effective on height velocity than usually obtained with chronic recombinant human growth hormone (rhGH) administration, underscores the desirability for improving the GHRP approach. This includes further optimization and extension of the range of the GHRP chemistry in order to
15 produce more effective biological actions.

In looking at these compounds, one looks at a varied series of biological effects such as the duration of action of GHRP. Other parameters that may substantially be affected by the chemistry of the GHRP include desensitization of the GHRP GH response, actions on the hypothalamus,
20 effects on SRIF release and action, effects on ACTH and PRL release as well as possible effects on putative subclasses of GHRP receptors. All of these actions are directly and/or indirectly dependent on the GHRP chemistry, pattern and efficiency of oral absorption as well as the metabolism and secretion of the particular GHRP.

25

SUMMARY OF THE INVENTION

We have now discovered a new group of compounds (sometimes referred to as secretagogues) that provide desirable *in vitro* and *in vivo* growth hormone releasing activity and have at least one other desirable
30 biological activity such as increased retention time. These compounds have the following formulas:

Formula I:

A₁-A₂-X

wherein A₁ is Aib (aminoisobutyric acid), inip (isonipecotyl) or ABU (aminobutyric acid). The Aib residue can be substituted or unsubstituted.

- 5 -

Preferred substituents include C₁-C₆ alkyl and halogens. Aib is preferably unsubstituted. Aib is preferably α Aib. ABU is preferably γ ABU or $\alpha\gamma$ ABU, more preferably α,γ ABU;

A₂ is any natural L-amino acid or Pal, or their respective D-isomers, D α Nal (5 α -naphthyl-D-alanine) or D β Nal (β -naphthyl-D-alanine), preferably A₂ is DTrp, D α Nal (α -naphthyl-D-alanine) or D β Nal (β -naphthyl-D-alanine), more preferably A₂ is DTrp or D α Nal;

X is (1) R₁-R₂-Z, wherein R₁ and R₂ are any natural L-amino acid, Pal, α Nal, β Nal, DpCl, CH_x, where CH_x is cyclohexyl, CH_xAla, or any of 10 their respective D-isomers, preferably R₁ is DPro, DTrp, D β Nal or DPhe, more preferably R₁ is DPro or DTrp; and R₂ is preferably Gly, Phe, Pro, DPro, DPhe, DPal, DLeu, DHis, DVal, DGln, DArg, DAla, DSer, DThr, Dlle, Arg, Orn Lys, Ala, Pal, Thr, Val, PheCH_x, CH_xAla or CH_x, where x is preferably 1-8, more preferably 1 to 5; and Z is 15 CONH₂ or COOH;

(2) DpR₃Phe-R₄-Z, wherein R₃ is a halogen, preferably Cl, and R₄ is any natural L-amino acid or Pal, or their respective D-isomers, preferably R₄ is Phe or Arg, and Z is CONH₂ or COOH;

(3) NH(CH₂)_nNH, where n is 1 to 8, such as -2-aminoethylamide, - 20 3-aminopropylamide, -4-aminobutylamide, -5-aminopentylamide, or -6-aminohexylamide;

(4) R₅-R₆, wherein R₅ is any natural L-amino acid, Pal, α Nal, β Nal, DpCl, CH_x where x is 1 to 10, or any of their respective D-isomers, preferably R₅ is DPro or DTrp, and R₆ is

25 (a) diisobutylamide

(b) dipropylamide

(c) butylamide

(d) pentylamide

(e) dipentylamide

30 (f) C(=O) (substituted heteroalicyclic or heteroaromatic)

such as -piperidine-3-methyl-

benzylether

-N-diethylnipectamide

- 6 -

-N-piperazine methylsulfonamide

-diethylamide

-m-methylpiperidine

-3,3-diphenylpropylamide

5 -4-piperidino piperidinamide

-4-phenyl-piperidinamide

-N-methylpiperazine

-2-morpholinoethylamine

-spiroindole methylsulfonamide

10 -pyrrolidine amide

-indoleamide

-3-piperidine methanolamide

-tropin amide

-2-aminoethylamide

15 -3-aminopropylamide

-4-aminobutylamide

-5-aminopentylamide

-6-aminohexylamide;

(5) DTrp Phe ArgR₇, wherein R₇ is NH(CH₂)_nNH, where n is 1 to 8,
20 such as -2-aminoethylamide, -3-aminopropylamide, -4-

aminobutylamide, -5-aminopentylamide, or -6-aminohexylamide; or

(6) R₈-R₉-R₁₀-Z, wherein R₈ is DTrp, DPro, DαNal or DβNal,

preferably R₈ is DTrp or DPro, R₉ is any natural L-amino acid or Pal, or
their respective D-isomers, preferably R₉ is Phe, DVal, DPro, DIle, Ile,

25 more preferably R₉ is Phe, DVal or DPro; R₁₀ is any natural L-amino
acid or Pal, or their respective D-isomers, preferably R₁₀ is Lys or Arg,
and Z is CONH₂ or COOH, preferably Z is CONH₂.

Formula II:

A₁-X'

30 wherein A₁ is Aib, inip, ABU, IMC (imidazole carboxylic acid), Ava, 4-IMA
(Nα-imidazole acetic acid), βAla, Ileu, Trp, His, DpCl, CHx, or any of their
respective D-isomers. The Aib residue can be substituted or unsubstituted.
Preferred substituents include N- and N-,N- C₁-C₆ alkyl, halogens, N- and N-
,N-2 hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl and 3-hydroxyisobutyl.

- 7 -

Aib is preferably unsubstituted. Aib is preferably α Aib. ABU is preferably γ ABU or $\alpha\gamma$ ABU, more preferably α,γ ABU; and

X' is (1) R_1-R_2-Z , wherein R_1 is any natural L-amino acid or Pal, or their respective D-isomers, D α Nal or D β Nal, preferably R_1 is DTrp, D α Nal or D β Nal, more preferably R_1 is DTrp or D α Nal, and R_2 is any natural L-amino acid, Pal, α Nal, β Nal, DpCl, Aib, preferably α Aib, CH_x where x is 1 to 10, or CH_xAla, or any of their respective D-isomers, and Z is CONH₂ or COOH, preferably Z is CONH₂; or

(2) R_3-R_4 , wherein R_3 is any natural L-amino acid or Pal, or their respective D-isomers, D α Nal or D β Nal, preferably R_3 is DPro, DTrp, D α Nal or D β Nal, more preferably R_3 is DPro, DTrp or D α Nal, and R_4 is NH(CH₂)_nNH, where n is 1 to 8, such as -2-aminoethylamide, -3-aminopropylamide, -4-aminobutylamide, -5-aminopentylamide, or -6-aminohexylamide.

The organic and inorganic addition salts thereof are also included.

In an alternative embodiment the compound has the formula

Formula III: A_1-Y ,

wherein A_1 is Aib, inip, ABU, β Ala, His, Sar or any of their respective D-isomers. The Aib residue can be substituted or unsubstituted. Preferred substituents include N- and N-, N-C₁-C₆ alkyl, halogens, N- and N-, N-2 hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl and 3-hydroxyisobutyl. Aib is preferably unsubstituted. A_1 is preferably Aib, inip or ABU. More preferably Aib is α Aib. Abu is preferably γ Abu or α,γ Abu, more preferably α,γ Abu.

Y is $A_2-A_3-A_4-A_5-A_6-Z'$,
 $A_2-A_3-A_4-A_5-Z'$ or $A_2-A_3-A_4-Z'$


wherein A_2 is A_5-A_2 or A_2 ,
 wherein A_5 is a spacer amino acid such as His,
 A_2 is as defined above for A_2 . A_2 is preferably DTrp, D α Nal or D β Nal. A_2 is more preferably DTrp.

- 8 -


A₃, A₄ and A₅ are any natural L-amino acid, Pal, αNal, βNal, Nle, Arg-DPro, DPCl, D or L (CHX), cyclohexylalanine (CHXAla), or any of their respective D-isomers, preferably A₃ is DPro, DTrp, DβNal or DPhe, more preferably A₃ is DPro or DTrp; and A₄ is preferably Gly, Phe, Pro, Ile, DPro, DPhe, DPal, DLeu, DHis, DVal, DGln, DIle, DNle, DArg, DAla, DSer, DThr, DIle, Arg, Orn Lys, Ala, Pal, Thr, Val, PheCHX, CHXAla or CHX. A₄ is preferably DSer, DAug, DPro, DTrp, DVal, DIle, DThr, DNval, DNle, Ile, Pro, Phe and still more preferably, A₄ is DPro. A₅ is preferably Ile, Arg, Pal, DArg, DSer, Lys and Arg-DPro. More preferably A₅ is Arg, DArg, and Lys.

10

Z' is NH₂, OH or alkylamino or aminoalkylamino, preferably the alkylamino is NH (C₁-C₁₀ alkyl) e.g. NH(CH₂)_nCH₃, where n is 1 to 10 such as




15 N di-(C₁-C₁₀ alkyl) e.g., N di-(CH₂)_n CH₃ such as




preferably the aminoalkylamino is a NH (C₁-C₁₀ alkylamino, e.g. NH(CH₂)_nNH₂ such as

20



N (di C₁-C₁₀ alkylamino), e.g., N [di-(CH₂)_nNH₂] such as



- 9 -

These compounds can be administered to an animal to promote release of serum growth hormone levels. Thus, these secretagogues can be used in a range of methods for example, to increase milk production, enhance body growth, treat hypothalamic pituitary dwarfism, osteoporosis, burns and renal failure, and to promote wound healing. They can also be used diagnostically. For example, to discover a loss of growth hormone receptor functioning.

DETAILED DESCRIPTION OF THE INVENTION

The compounds described herein are typically easy to synthesize, have efficacy at promoting an increase in serum growth hormone levels, and are desirable for large scale production and utilization. In addition, these compounds may be advantageous in having physiochemical properties which are desirable for the efficient delivery of such polypeptide compounds to a wide variety of animal species because of an improvement in at least one of bioavailability, absorption, metabolism, pharmacokinetics and excretion. The preferred methods of delivery are oral, nasal and continuous delivery utilizing special chemical/mechanical methods of delivery. Pulsed therapy is one preferred method of administration. These compounds have either of the following two formulas:

Formula I: A_1-A_2-X

wherein A_1 is Aib (aminoisobutyric acid), inip (isonipecotyl) or ABU (aminobutyric acid). The Aib residue can be substituted or unsubstituted.

Preferred substituents include C_1 - C_6 alkyl and halogens. Aib is preferably unsubstituted. Aib is preferably α Aib. ABU is preferably γ ABU or $\alpha\gamma$ ABU, more preferably α,γ ABU;

A_2 is any natural L-amino acid or Pal, or their respective D-isomers, D α Nal (α -naphthyl-D-alanine) or D β Nal (β -naphthyl-D-alanine), preferably A_2 is DTrp, D α Nal (α -naphthyl-D-alanine) or D β Nal (β -naphthyl-D-alanine), more preferably A_2 is DTrp or D α Nal;

X is (1) R_1-R_2-Z , wherein R_1 and R_2 are any natural L-amino acid, Pal, α Nal, β Nal, DpCl, CHx, CHxAla, or any of their respective D-isomers, preferably R_1 is DPro, DTrp, D β Nal or DPhe, more preferably R_1 is

- 10 -

DPro or DTrp; and R₂ is preferably Gly, Phe, Pro, DPro, DPhe, DPal, DLeu, DHis, DVal, DGln, DArg, DAla, DSer, DThr, Dlle, Arg, Orn Lys, Ala, Pal, Thr, Val, PheCHx, CHxAla or CHx, where x is preferably 1-8, more preferably 1 to 5; and Z is CONH₂ or COOH;

5 (2) DpR₃Phe-R₄-Z, wherein R₃ is a halogen, preferably Cl, and R₄ is any natural L-amino acid or Pal, or their respective D-isomers, preferably R₄ is Phe or Arg, and Z is CONH₂ or COOH;

(3) NH(CH₂)_nNH, where n is 1 to 8, such as -2-aminoethylamide, -3-aminopropylamide, -4-aminobutylamide, -5-aminopentylamide, or
10 -6-aminohexylamide;

(4) R₅-R₆, wherein R₅ is any natural L-amino acid, Pal, αNal, βNal, DpCl, CHx where x is 1 to 10, or any of their respective D-isomers, preferably R₅ is DPro or DTrp, and R₆ is

- (a) diisobutylamide
- 15 (b) dipropylamide
- (c) butylamide
- (d) pentylamide
- (e) dipentylamide
- (f) C(=O)(substituted heteroalicyclic or heteroaromatic)

20 such as -piperidine-3-methyl-
benzylether
-N-diethylnipectamide
-N-piperazine methylsulfonamide
-diethylamide
25 -m-methylpiperidine
-3,3-diphenylpropylamide
-4-piperidino piperidinamide
-4-phenyl-piperidinamide
-N-methylpiperazine
30 -2-morpholinoethylamine
-spiroindole methylsulfonamide
-pyrrolidine amide
-indoleamide
-3-piperidine methanolamide

- 11 -

-tropin amide
 -2-aminoethylamide
 -3-aminopropylamide
 -4-aminobutylamide
 5 -5-aminopentylamide
 -6-aminohexylamide;

(5) DTrp Phe Arg R₇, wherein R₇ is NH(CH₂)_nNH, where n is 1 to 8, such as -2-aminoethylamide, -3-aminopropylamide, -4-

aminobutylamide, -5-aminopentylamide, or -6-aminohexylamide; or

10 (6) R₈-R₉-R₁₀-Z, wherein R₈ is DTrp, DPro, DαNal or DβNal, preferably R₈ is DTrp or DPro, R₉ is any natural L-amino acid or Pal, or their respective D-isomers, preferably R₉ is Phe, DVal, DPro, Dlle, Ile, more preferably R₉ is Phe, DVal or DPro; R₁₀ is any natural L-amino acid or Pal, or their respective D-isomers, preferably R₁₀ is Lys or Arg, and Z is CONH₂ or COOH, preferably Z is CONH₂.

Formula II:

A₁-X'

wherein A₁ is Aib, inip, ABU, IMC (imidazole carboxylic acid), Ava, 4-IMA (Nα-imidazole acetic acid), βAla, Ileu, Trp, His, DpCl, CHx, or any of their
 20 respective D-isomers. The Aib residue can be substituted or unsubstituted. Preferred substituents include N- and N-,N- C₁-C₆ alkyl, halogens, N- and N-,N-2 hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl and 3-hydroxyisobutyl. Aib is preferably unsubstituted. Aib is preferably αAib. ABU is preferably γABU or αγABU, more preferably α,γABU; and

25 X' is (1) R₁-R₂-Z, wherein R₁ is any natural L-amino acid or Pal, or their respective D-isomers, DαNal or DβNal, preferably R₁ is DTrp, DαNal or DβNal, more preferably R₁ is DTrp or DαNal, and R₂ is any natural L-amino acid, Pal, αNal, βNal, DpCl, Aib, preferably αAib, CHx where x is 1 to 10, or CHxAla, or any of their respective D-isomers, and Z is CONH₂ or COOH, preferably Z is CONH₂; or

30 (2) R₃-R₄, wherein R₃ is any natural L-amino acid or Pal, or their respective D-isomers, DαNal or DβNal, preferably R₃ is DPro, DTrp, DαNal or DβNal, more preferably R₃ is DPro, DTrp or DαNal, and R₄ is

- 12 -

$\text{NH}(\text{CH}_2)_n\text{NH}$, where n is 1 to 8, such as -2-aminoethylamide, -3-aminopropylamide, -4-aminobutylamide, -5-aminopentylamide, or -6-aminohexylamide.

The organic and inorganic addition salts thereof are also included.

- 5 The abbreviations for the residues of amino acids used herein are in agreement with the standard nomenclature, and are set forth below:

Gly	Glycine
Tyr	L-Tyrosine
Ile	L-Isoleucine
Glu	L-Glutamic Acid
Thr	L-Threonine
Phe	L-Phenylalanine
Ala	L-Alanine
Lys	L-Lysine
Asp	L-Aspartic Acid
Cys	L-Cysteine
Arg	L-Arginine
Gln	L-Glutamine
Pro	L-Proline
Leu	L-Leucine
Met	L-Methionine
Ser	L-Serine
Asn	L-Asparagine
His	L-Histidine
Trp	L-Tryptophan
Val	L-Valine
Orn	L-Ornithine

- Moreover, all of the three letter-abbreviations of the amino acids preceded by a "D" indicate the dextro-isomer of the aminoacidic residue, and
10 glycine is considered to be included in the term naturally occurring L-amino acids. Other abbreviations used herein include the following:

Aib	aminoisobutyric acid
inip	isonipecotyl

- 13 -

ABU	aminobutyric acid
α Nal	α -naphthyl alanine
β Nal	β -naphthyl alanine
D α Nal	α -naphthyl-D-alanine
D β Nal	β -naphthyl-D-alanine
Pal	3-pyridyl alanine
CHx	cyclohexyl
CHxAla	L-cyclohexylalanine
Ava	Aminovaleric acid
IMA	N α -imidazole acetic acid
IMC	imidazole carboxylic acid
β Ala	β -Alanine

In one embodiment of the present invention, a group of preferred compounds includes:

γ ABUDTrpDTrpArgCOOH

α, γ ABUDTrpDTrpArgNH₂

α, γ ABUDTrpDTrpOrnNH₂

α, γ ABUD α NalDTrpLysNH₂

α, γ ABUD α NalDTrpArgNH₂

α, γ AbuD α NalDTrpArgNH₂

α AibDTrpDTrpArgNH₂

α AibD α NalDTrpArgNH₂

α AibDTrpDTrpArgCOOH

α AibD α NalDTrpArgCOOH

α AibD α TrpDTrpArgNH₂

α AibDTrpDPheArgNH₂

inipD α NalDTrpPheNH₂

inipD α NalDTrpCHxAlaNH₂

inipD α NalDTrpPheCOOH

inipD α NalDTrpPalNH₂

inipD α NalDTrpThrNH₂

inipD α NalDTrpValNH₂

- 14 -

inipD α NalD β NalPheNH₂
 inipD α NalDTrpPheCOOH
 inipD β NalDTrpPheNH₂
 α AibDTrpDProGlyNH₂
 α AibDTrpDProPheNH₂
 α AibDTrpDProProNH₂
 α AibDTrpDProDProNH₂
 α AibDTrpDProDPheNH₂
 α AibDTrpDProDPalNH₂
 α AibDTrpDProDTrpNH₂
 α AibDTrpDProDLeuNH₂
 α AibDTrpDProDHisNH₂
 α AibDTrpDProDValNH₂
 α AibDTrpDProGlnNH₂
 α AibDTrpDProArgNH₂
 α AibDTrpDProLysNH₂
 α AibDTrpDProDAlaNH₂
 inipD α NalDpClPhePheNH₂
 inipD α NalDpClPheArgNH₂
 inipD α NalDTrpDProNH₂
 α AibDTrpDProDSerNH₂
 α AibDTrpDProDThrNH₂ and
 α AibDTrpDProDlleNH₂.

In another embodiment of the present invention, a group of preferred compounds includes:

inipDTrpDTrpPheLysNH₂
 inipD β NalDTrpPheLysNH₂
 5 γ ABUD β NalDTrpPheLysNH₂
 α,γ ABUDTrpDTrpPheLysNH₂
 β AlaDTrpDTrpPheLysNH₂
 α,γ ABUD β NalDTrpPheLysNH₂
 α,γ ABUDTrpDTrpPheArg NH₂

- 15 -

- α, γ ABUD α NalDTrpPheArgNH₂
 inipD β NalDTrpPheLysNH₂
 inipDTrpDTrpPheArgNH₂
 β AlaD α NalDTrpPheArgNH₂
 5 α AibDTrpDTrpPheArgNH₂
 α AibDTrpDTrpPheArgCOOH
 inipDTrpDTrpPheArgCOOH
 inipD α NalDTrpPheArgNH₂
 inipD α NalDTrpPheArgCOOH
 10 inipD α NalD β NalPheArgNH₂
 inipD α NalDTrpPheDSerNH₂
 inipD α NalDTrpPheDThrNH₂
 inipD α NalDTrpPheGlyNH₂
 inipD α NalDTrpPheGlnNH₂
 15 inipD α NalDTrpPheDGlnNH₂
 α AibD α NalDTrpPheGlnNH₂
 inipD α NalDTrpPheDHisNH₂
 α AibDTrpDProPheArgNH₂
 α AibDTrpDProPheDArgNH₂
 20 α AibDTrpDProDValArgNH₂
 α AibDTrpDProDValDLysNH₂
 α AibDTrpDProDValDArgNH₂
 α AibDTrpDProDProArgNH₂
 α AibDTrpDProDProDPalNH₂
 25 α AibDTrpDProDProDArgNH₂
 α AibDTrpDProDlleDArgNH₂
 α AibDTrpDProDlleArgNH₂
 α AibDTrpDProDProDLysNH₂ and
 α AibDTrpDProDlleArgNH₂.

- 30 In the above Formula I, where X is R₅-R₆ and R₆ is a C(=O)
 (substituted heteroalicyclic or heteroaromatic), the heteroatom is selected
 from the group consisting of O, N, S and P.

- 16 -

The heteroalicyclic moiety preferably contains 2 to 12 carbon atoms, more preferably 3 to 8 carbon atoms. The heteroaromatic moiety preferably contains 5 to 12 carbon atoms, more preferably 5 to 11 carbon atoms. Substituents include NH_2 , $\text{C}_1\text{-C}_{12}$ lower alkyl, and as listed below.

5 Examples include piperidine-3-methyl-benzylether, N-diethylnipectamide, N-piperazine methylsulfonamide, diethylamide, m-methylpiperidine, 3,3-diphenylpropylamide, 4-piperidino piperidinamide, 4-phenyl-piperidinamide, N-methyl 1-piperiazine, 2-morpholinoethylamine, spiroindole methylsulfonamide, pyrrolidine amide, indoleamide, 3-piperidine
10 methanol amide, tropin amide, 2-aminoethylamide, 3-aminopropylamide, 4-aminobutylamide, 5-aminopentylamide, 6-aminohexylamide. Preferred substituted heteralicyclic or heteroaromatic include N-diethylnipectamide, piperidine-3-methyl-benzylether, N-piperazine methyl sulfonamide, diethylamide and m-methylpiperidine. Even more preferred are N-
15 diethylnipectamide and piperidine-3-methyl-benzylether.

 Preferably, the compound has the structure AibDTrpX , where X is DProNH_2 , $\text{DPro-diisobutylamide}$, DProbutylamide , $\text{DPro-C(=O)(substituted heteroalicyclic or heteroaromatic)}$, and $\text{DTrp-Phe-Arg-5-aminopentamide}$ and organic and inorganic addition salts thereof. More preferably, X is $\text{DPro-diisobutylamide}$, $\text{DPro-C(=O)(substituted heteroalicyclic or heteroaromatic)}$
20 and $\text{DTrp PheArg-5-aminopentamide}$, and organic and inorganic addition salts thereof. Still more preferably, X is $\text{DPro-diisobutylamide}$ or $\text{DTrp-Phe-Arg-5-aminopentamide}$, and organic and inorganic addition salts thereof. Even more preferably, X is $\text{DPro-diisobutylamide}$ and organic and inorganic
25 addition salts thereof.

 In an alternative embodiment the compound has the formula



wherein A_1 is Aib, inip, ABU, βAla , His, Sar or any of their respective D-isomers. The Aib residue can be substituted or unsubstituted. Preferred
30 substituents include N- and N-, $\text{N-C}_1\text{-C}_6$ alkyl, halogens, N- and N-, N-2 hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl and 3-hydroxyisobutyl. Aib is preferably unsubstituted. A_1 is preferably Aib, inip or ABU. More preferably Aib is αAib . Abu is preferably γAbu or $\alpha,\gamma\text{Abu}$, more preferably $\alpha,\gamma\text{Abu}$.

- 17 -

Y is A₂-A₃-A₄-A₅-A₆-Z',

A₂-A₃-A₄-A₅-Z' or A₂-A₃-A₄-Z'


wherein A₂' is A₅-A₂' or A₂'

wherein A₅ is a spacer amino acid such as His,

5 A₂' is as defined above for A₂. A₂' is preferably DTrp, DαNal or DβNal. A₂' is more preferably DTrp.


A₃, A₄ and A₅ are any natural L-amino acid, Pal, αNal, βNal, Nle, Arg-DPro, DPCl, D or L (CHX), cyclohexylalanine (CHXAla), or any of their respective D-isomers, preferably A₃ is DPro, DTrp, DβNal or DPhe, more
 10 preferably A₃ is DPro or DTrp; and A₄ is preferably Gly, Phe, Pro, Ile, DPro, DPhe, DPal, DLeu, DHis, DVal, DGIln, DIle, DNle, DArg, DALa, DSer, DThr, DIle, Arg, Orn Lys, Ala, Pal, Thr, Val, PheCHX, CHXAla or CHX. A₄ is preferably DSer, DAug, DPro, DTrp, DVal, DIle, DThr, DNVal, DNle, Ile, Pro, Phe and still more preferably, A₄ is DPro. A₅ is preferably Ile, Arg, Pal, DArg,
 15 DSer, Lys and Arg-DPro. More preferably A₅ is Arg, DArg, and Lys.

Z' is NH₂, OH or (aminoalkyl) or (aminoalkylamino), preferably the aminoalkyl is NH (C₁-C₁₀ alkyl) e.g. NH(CH₂)_nCH₃, where n is 1 to 10 such as




20

N di-(C₁-C₁₀ alkyl) e.g., N di-(CH₂)_n CH₃ such as




preferably the alkylamino is a NH (C₁-C₁₀ alkylamino, e.g. NH(CH₂)_nNH₂ such

25 as



N (di C₁-C₁₀ alkylamino), e.g., N [di-(CH₂)_nNH₂] such as



5 Preferred examples include moieties such as -2-aminoethylamide, -3-aminopropylamide, -4-aminobutylamide, -5-aminopentylamide, or -6-aminohexylamide; N-dimethylamide; N-diethylamide; N-dipropylamide; N-dibutylamide; N-diisobutylamide; N-dipentylamide; N-dihexylamide;

10 A particularly preferred embodiment is Aib-Y, more preferably α Aib-Y.

Y is preferably A₂'-DPro-A₄-A₅-A₆-Z'; A₂'-A₃-A₄-Z'; or A₂'-A₃-A₄-A₅-Z'. Y is more preferably A₂'-DPro-A₄-Z' or A₂'-DPro-A₄-Z' or A₂'-DPro-A₄-A₅-Z'. Still more preferably Y is A₂'-DPro-A₄-A₅-Z'. Z' is preferably -NH₂.

Preferred embodiments include

- 15 α Aib-DTrp-DPro-A₄-A₅-A₆-Z';
 α Aib-DTrp-DPro-A₄-A₅-Z';
 α Aib-DTrp-DPro-A₄-Z';
 α Aib-DTrp-DPro-A₄-Arg-NH₂;
 α Aib-DTrp-DPro-A₄-Arg-A₆-NH₂;
 20 α Aib-DTrp-DPro-A₄-Arg-Gly-NH₂;
 α Aib-D α Nal-DPro-A₄-A₅-A₆-Z';
 α Aib-D α Nal-DPro-A₄-A₅-Z';
 α Aib-D α Nal-DPro-A₄-Z';
 α Aib-D α Nal-DPro-A₄-NH₂;
 25 α Aib-D α Nal-DPro-A₄-Arg-NH₂;
 and α Aib-D α Nal-DPro-A₄-Arg-Gly-NH₂.

A₄ is preferably Dlle, DThr, DNle, DVal, DGln, DAla, DPhe, DTrp, DNVal and Arg.

Exemplary representatives of α Aib-A₂'-DPro-A₄-Arg-Z' include

30 α AibDTrpDProDlleArgNH₂;

- 19 -

α AibDTrpDProDThrArgNH₂;
 α AibDTrpDProDValArgNH₂;
 α AibDTrpDProDNleArgNH₂; and
 α AibD α NalDProDlleDArgNH₂.

5 Exemplary representatives of:

α Aib-A₂-DPro-A₄-Z include

α Aib-DTrp-DPro-DThr-NH₂;

α Aib-DTrp-DPro-DGln-NH₂;

α Aib-DTrp-DPro-Arg-NH₂;

10 α Aib-DTrp-DPro-DAla-NH₂;

α Aib-DTrp-DPro-DPhe-NH₂;

α Aib-DTrp-DPro-DTrp-NH₂;

α Aib-DTrp-DPro-DVal-NH₂;

α Aib-DTrp-DPro-DNVal-NH₂; and

15 α Aib-DTrp-DPro-Dlle-NH₂;

Exemplary representatives of α Aib-A₂-DPro-A₄-Arg-A₆-Z include
compounds of the formula α Aib-A₂-DPro-A₄-Arg-Gly-NH₂ such as

α Aib-DTrp-DPro-Dlle-Arg-Gly-NH₂;

α Aib-DTrp-DPro-DThr-Arg-Gly-NH₂; and

20 α Aib-DTrp-DPro-DNle-Arg-Gly-NH₂.

Representative compounds are set forth below:

inipD α NalDTrpNH₂;

inipD α NalDValNH₂;

α AibDTrpDValNH₂;

25 α AibDTrpDProDSerNH₂;

α AibDTrpDProDArgNH₂;

α AibDTrpDProDPheNH₂;

α AibDTrpDProDTrpNH₂;

α AibDTrpDValDValNH₂;

30 α AibDValDProDValNH₂;

α AibDValDValDValNH₂;

α AibDTrpDProDLysNH₂;

- 20 -

- α AibDProDProDValNH₂;
inipD α NalDTrpDValNH₂;
 α AibDTrpDProIleNH₂;
 α γ AbuD α NalDTrpDIleNH₂;
5 inipD α NalDTrpDProIleNH₂;
inipD α NalDTrpPheIleNH₂;
inipD α NalDTrpDValArgNH₂;
 α AibDTrpDProDValDValNH₂;
 α AibDTrpDProDProDPalNH₂;
10 α AibDTrpDProDValArgDProNH₂;
 α AibDTrpDProDIleDArgNH₂;
 α γ AbuDTrpDTrpDIleNH₂;
inipD α NalDTrpPheDValNH₂;
 α AibDTrpDProValNH₂;
15 α AibDTrpDIleDIleNH₂;
 α AibDTrpDProLeuNH₂;
 α AibDTrpDProThrNH₂;
DHisDTrpDProDValArgNH₂;
DHisDTrpDProDThrNH₂;
20 α AibDTrpDProDIleNH₂;
 α AibDTrpDPheDValNH₂;
 α AibDTrpDProDValDArgNH₂;
 α AibDTrpDProDAlaNH₂;
 α AibDTrpDProDProNH₂;
25 α AibDTrpDProArgNH₂;
 α AibDTrpDProDValNH₂;
inipD α NalDTrpDProNH₂;
 α AibD α NalDProDValDArgNH₂;
 α AibD α NalDProDIleDArgNH₂;
30 α AibDTrpDProDProDLysNH₂;
 α AibHisD α NalDPheLysNH₂;
 α AibHisDTrpDProDValNH₂;

- α AibHisDTrpDProDlleNH₂;
 α AibHisDTrpDProValArgNH₂;
 α AibHisDTrpDProDValArgNH₂;
 α AibD α NalDProDValNH₂;
5 α AibDTrpDProDThrArgNH₂;
 α AibDTrpDProDNleArgNH₂;
 α AibDTrpDProDNValArgNH₂;
 α AibDTrpDProIleArgNH₂;
 α AibDTrpDProDProArgNH₂;
10 α AibDTrpDProProArgNH₂;
 α AibDTrpDProDProDArgNH₂;
 α AibDTrpDProDlleArgNH₂;
 α AibDTrpDProPheDSerNH₂;
 α AibDTrpDProPheArgNH₂;
15 α AibDTrpDProDValArgNH₂;
SarDTrpDTrpPheArgNH₂;
 α AibD α NalDProDProArgNH₂;
 α AibD α NalDProDNValArgNH₂;
 α AibD α NalDProDlleArgNH₂;
20 α AibD α NalDProDValLysNH₂;
 α AibD α NalDProDThrArgNH₂;
 α AibD α NalDProDThrArgNH₂;
 α AibD α NalDProDValArgNH₂;
 α AibD α NalDProDValArgNH₂;
25 α AibDTrpDProDNleNH₂;
 α AibDTrpDProDNValNH₂.
 α AibDTrpDProDlle-X_a, where X_a is
2-aminoethylamide,
5-aminopentylamide, or
30 3-aminopropylamide.
 α AibDTrpDProDVal-X_b, where X_b is
2-aminoethylamide,
dimethylamide, or

- 22 -

diethylamide.

α AibDTrpDProDPro- X_c , where X_c is

2-aminoethylamide.

The following compounds are preferred

5 α AibDTrpDProDlle X_d , where X_d is

5-aminopentylamide,

3-aminopropylamide,

2-aminoethylamide, or

4-aminobutylamide

10 α AibDTrpDProDVal X_e , where X_e is

N-dimethylamide,

N-diethylamide, or

2-aminoethylamide;

α AibDTrpDProDVal X_f , where X_f is

15 5-aminopentylamide;

α AibDTrpDProDNle X_g , where X_g is

5-aminopentylamide;

α AibDTrpDProDProArgNH₂;

α AibDTrpDProDValDArgNH₂;

20 α AibDTrpDProDValArgNH₂;

α AibDTrpDProDlleArgNH₂;

α AibD α NalDProDValArgNH₂;

α AibD α NalDProDValArgNH₂;

α AibD α NalDProDlleArgNH₂;

25 α AibD α NalDProDValLysNH₂;

inipD α NalD α NalPheArgNH₂;

α AibDTrpDProDThrArgNH₂;

α AibDTrDProDNleArgNH₂;

α AibDTrpDProDNValArgNH₂;

30 α AibDTrpDProDlleArgGlyNH₂;

α AibDTrpDProDProDlleArgGlyNH₂;

α AibDTprDProDNleArgGlyNH₂; and

α AibDTrpDProDThrArgGlyNH₂;

- 23 -

In one embodiment one uses compound from compounds having the formula

$\alpha\text{AibDTrpDProDProA}_4\text{ArgNH}_2$ or
 $\alpha\text{AibDTrpDProDProA}_4\text{ArgGlyNH}_2$.

5 Preferred examples are selected from the group consisting of

$\alpha\text{AibDTrpDProDlleArgNH}_2$
 $\alpha\text{AibDTrpDProDlleArgGlyNH}_2$
 $\alpha\text{AibDTrpDProDProDlleArgNH}_2$, and
 $\alpha\text{AibDTrpDProDProDlleArgGlyNH}_2$.

10 In an alternate embodiment, the following peptides are of interest:

$\text{D}\beta\text{NalAlaTrpDPheLysGlnGlyNH}_2$
 $\text{DAlaDTrpAlaTrpDPheLysValGlyNH}_2$
 $\text{DAlaD}\beta\text{NalAlaTrpDPheLysGlnGlyGlyGlyNH}_2$
 $\text{DAlaDTrpAlaTrpDPheLysHisGlyNH}_2$

15 These secretagogues can be used therapeutically for any use for which growth hormone can be used, such as treating hypothalamic pituitary dwarfism, osteoporosis, burns, and renal failure for acute use, for non-union bone fracture, and to promote wound healing. Additionally, it can be used to promote recovery from surgery, and acute/chronic debilitating medical
20 illnesses. Beneficial anabolic effects result on skin, muscle and bone in relation to the aging process with a concomitant decrease in body fat. Treatment of cancer patients by these peptides is also included, for example, prevention and/or reduction of cachexia in cancer patients. These therapeutic uses are accomplished by using a therapeutically effective
25 amount of the compound. Such an amount is that needed to promote the release of serum growth hormone levels as discussed, infra.

The compounds of this invention may also be used to enhance blood GH levels in animals; enhance milk production in cows; enhance body growth in animals such as, e.g., humans, sheep, bovines, and swine, as well
30 as fish, fowl, other vertebrates and crustaceans; and increase wool and/or fur production in mammals. The amount of body growth is dependent upon the sex and age of the animal species, quantity and identity of the growth

- 24 -

hormone releasing compound being administered, route of administration, and the like.

Also, the compounds of this invention increase serum GH in humans; enhance body growth in short stature children; decrease body fat and
5 improve protein metabolism in select children; improve protein metabolism of the skin, muscle, bone while decreasing body fat of the elderly, particularly when GH deficiency is present.

These compounds are also useful for improving serum lipid pattern in humans by decreasing in the serum the amount of serum cholesterol and
10 low density lipoprotein, and increasing in the serum the amount of the high density lipoprotein.

The novel secretagogues of this invention can be synthesized according to the usual methods of solution and solid phase peptide chemistry, or by classical methods known in the art.

15 In accordance with another embodiment of the present invention, a method is provided for promoting release and/or elevation of growth hormone levels in the blood of an animal. This method of promoting the release and/or elevation of growth hormone levels can also be used to therapeutically treat the aforesaid diseases. Said methods comprise
20 administering to an animal an effective dose of at least one of the above-described compounds. In one embodiment, this method is used in animals other than humans.

The compounds of this invention can be administered by oral, parenteral (intramuscular (i.m.), intraperitoneal (i.p.), intravenous (i.v.) or
25 subcutaneous (s.c.) injection), nasal, vaginal, rectal or sublingual routes of administration as well as intrapulmonary inhalation can be formulated in dose forms appropriate for each route of administration. Parenteral administration is preferred.

Solid dose forms for oral administration include capsules, tablets,
30 pills, powders and granules. In such solid dose forms, the active compound is mixed with at least one inert carrier such as sucrose, lactose, or starch. Such dose forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dose

- 25 -

forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dose forms for oral administration include emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides, such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dose forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in a medium of sterile water, or some other sterile injectable medium immediately before use.

The amount of secretagogues or combination of compounds of the present invention administered will vary depending on numerous factors, e.g., the particular animal treated, its age and sex, the desired therapeutic affect, the route of administration and which polypeptide or combination of polypeptides are employed. In all instances, however, a dose effective (therapeutically effective amount) to promote release and elevation of growth hormone level in the blood of the recipient animal is used. Ordinarily, this dose level falls in the range of between about 0.1 μ g to 10mg of total compound per kg of body weight. The preferred amount can readily be determined empirically by the skilled artisan based upon the present disclosure.

For example, in humans when the mode of administration is i.v. the preferred dose level falls in the range of about 0.1 μ g to 10 μ g of total secretagogue per kg of body weight, more preferably, about 0.5 μ g to 5 μ g of total secretagogue per kg of body weight, still more preferably about 0.7 μ g

- 26 -

about 3.0 μ g per kg of body weight. When combinations of growth hormone releasing compounds are used, lower amounts of the presently described peptide can be used. For example, combining the presently described secretagogues with, for example, a synergistic compound in Group I of U.S. Patent No. 4,880,778 such as GHRH, or U.S. Patent No. 5,663,146 or 5,486,505, a preferred range is about 0.1 μ g to about 5 μ g of the presently described compound per kg of body weight and about 0.5 μ g to about 15.0 μ g of synergistic compound (e.g. GHRH) and more preferably about 0.1 μ g to about 3 μ g of the present compound with about 1.0 μ g to about 3.0 μ g of the synergistic compound per kg of body weight.

When the mode of administration is oral, greater amounts are typically needed. For example, in humans for oral administration, the dose level is typically about 30 μ g to about 1200 μ g of compound per kg of body weight, more preferably about 70 μ g to about 600 μ g of compound per kg of body weight, still more preferably, about 200 μ g to about 600 μ g of total compound per kg of body weight. Cows and pigs require about the same dose level as humans, while rats typically require higher dose levels. The exact level can readily be determined empirically based upon the present disclosure.

In general, as aforesaid, the administration of combinations of growth hormone releasing peptides will allow for lower doses of the individual growth hormone releasing compounds to be employed relative to the dose levels required for individual growth hormone releasing compounds in order to obtain a similar response, due to the synergistic effect of the combination.

Also included within the scope of the present invention are compositions that comprise, as an active ingredient, the organic and inorganic addition salts of the above-described polypeptides and combinations thereof; optionally, in association with a carrier, diluent, slow release matrix, or coating.

The organic or inorganic addition salts of the growth hormone releasing compounds and combinations thereof contemplated to be within the scope of the present invention include salts of such organic moieties as acetate, trifluoroacetate, oxalate, valerate, oleate, laurate, benzoate, lactate,

- 27 -

tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthalate, and the like; and such inorganic moieties as Group I (i.e., alkali metal salts), Group II (i.e. alkaline earth metal salts) ammonium and protamine salts, zinc, iron, and the like with counterions such as chloride, bromide, sulfate, phosphate and the like, as well as the organic moieties referred to above.

Pharmaceutically acceptable salts are preferred when administration to human subjects is contemplated. Such salts include the non-toxic alkali metal, alkaline earth metal and ammonium salts commonly used in the pharmaceutical industry including sodium, potassium, lithium, calcium, magnesium, barium, ammonium and protamine salts which are prepared by methods well known in the art. The term also includes non-toxic acid addition salts which are generally prepared by reacting the compounds of this invention with a suitable organic or inorganic acid. Representative salts include hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate and the like.

The invention will be further illustrated by the following non-limiting examples.

20 **EXAMPLES OF THE INVENTION**

The following examples are designed to illustrate certain aspects of the present invention. The examples are not intended to be comprehensive of all features and all embodiments of the present invention, and should not be construed as limiting the claims presented herein.

25 **General Methods for Synthesis**

¹H NMR spectra were measured (SiMe₄ internal standard) on a GE-500 (500 MHz) Spectrometer. Mass spectra data were obtained by using a "Lasermat" Laser Desorption Mass Spectrometry. Reagents were obtained from commercial sources and used without further purification. Solvents were dried according to standard procedures. Scheme 1 can be utilized for additions with any amine group recorded in Table 1.

Example 1

Synthesis of the Growth Hormone Releasing Peptides

- 28 -

Paramethyl benzhydrylamine hydrochloride (pMe-BHA HCl) resin is placed in a reaction vessel on a commercially available automated peptide synthesizer. The resin is substituted with free amine up to a loading of about 5 mmoles per gram. The compounds are prepared by coupling individual amino acids starting at the carboxy terminus of the peptide sequence using an appropriate activating agent, such as N,N'-dicyclohexylcarbodiimide (DCC). The alpha amine of individual amino acids are protected, for example, as the t-butyloxycarbonyl derivative (t-Boc) and the reactive side chain functionalities are protected as outlined in Table 1.

Table 1

Side Chain Protecting Groups Suitable for Solid Phase Peptide Synthesis

Arginine	N ^ε -Tosyl
Aspartic Acid	O-Benzyl
Cysteine	S-para-Methylbenzyl
Glutamic Acid	O-Benzyl
Histidine	N ^{im} -Tosyl
Lysine	N ^ε -2,4-Dichlorobenzyloxycarbonyl
Methionine	S-Sulfoxide
Serine	O-Benzyl
Threonine	O-Benzyl
Tryptophan	N ⁱⁿ -Formyl
Tyrosine	O-2,6-Dichlorobenzyl

Prior to incorporation of the initial amino acid, the resin is agitated three times (about one minute each) with dichloromethane (CH₂Cl₂; about 10 ml/gm of resin), neutralized with three agitations (about two minutes each) of N,N-diisopropylethylamine (DIEA) in dichloromethane (10:90; about 10 ml/gm of resin) and agitated three times (about one minute each) with dichloromethane (about 10 mL/gm of resin). The initial and each of the subsequent amino acids are coupled to the resin using a preformed symmetrical anhydride using about 6.0 times the total amount of the reaction capacity of the resin of a suitably protected amino acid and about 2.0 times the total amount of the binding capacity of the resin of DIC in an

- 29 -

appropriate amount of dichloromethane. For amino acids with a low dichloromethane solubility, N,N-dimethylformamide (DMF) is added to achieve a homogenous solution. Generally, the symmetrical anhydride is prepared up to 30 minutes prior to introduction into the reaction vessel at room temperature or below. The dicyclohexylurea that forms upon preparation of the symmetrical anhydride is removed via gravity filtration of the solution into the reaction vessel. Progress of the coupling of the amino acid to the resin is commonly monitored via a color test using a reagent such as ninhydrin (which reacts with primary and secondary amines). Upon complete coupling of the protected amino acid to the resin (>99%), the alpha amine protecting group is removed by treatment with acidic reagent(s). A commonly used reagent consists of a solution of trifluoroacetic acid (TFA) in dichloromethane (33:66).

After the desired amino acid sequence has been completed, the desired peptide can be cleaved from the resin support by treatment with a reagent such as hydrogen fluoride (HF) which not only cleaves the peptide from the resin, but also cleaves most commonly used side-chain protecting groups. When the BHA or p-Me-BHA resin is used, HF treatment results directly in free peptide amides. When an amino acid-Merrifield resin is used, free peptide alkylamides are cleaved by treatment with an appropriate amine (in this case, use of Boc-N^ε-FMOC-Lys would allow simultaneous removal of the FMOC group).

The complete procedure for incorporation of each individual amino acid residue onto the resin is outlined in Table 2.

25

- 30 -

Table 2Procedure for Incorporation of Individual Amino Acids onto a Resin

	Reagent	Agitations	Time/Agitation
1.	Dichloromethane	3	1 min.
2.	TFA-Dichloromethane (33:66)	1	2 min.
3.	TFA-Dichloromethane (33:66)	1	20 min.
4.	Dichloromethane	3	1 min.
5.	DIEA, DMF (10:90)	2	2 min.
6.	Dichloromethane	3	1 min.
7.	Boc amino acid/DIC	1	15-120 min *
8.	Dichloromethane	3	1 min.
10.	Monitor progress of the coupling reaction **		
11.	Repeat steps 1-12 for each individual amino acid		

* Coupling time depends upon the individual amino acid.

5 ** The extent of coupling can be generally monitored by a color test. If the coupling is incomplete, the same amino acid can be recoupled by a different protocol, e.g. HOBt active ester. If the coupling is complete the next amino acid can then be coupled.

10 Using this procedure the compounds described in Tables 3, 4 and 5 were made.

Example 2In Vivo GH Release in Rats

15 Immature female Sprague-Dawley rats were obtained from the Charles River Laboratories (Wilmington, MA). After arrival they were housed at 25°C with a 14:10 hour light:dark cycle. Water and Purina rat chow were available *ad libitum*. Pups were kept with their mothers until 21 days of age.

- 31 -

Twenty-six day old rats, six rats per treatment group, were anesthetized interperitoneally with 50 mg/kg of pentobarbital 20 minutes prior to i.v. treatment with peptide. Normal saline with 0.1% gelatin was the vehicle for intravenous (i.v.) injections of the peptides. The anesthetized rats, weighing 55-65 grams, were injected i.v. with the quantity of grown hormone releasing compounds indicated in Table 3. Injection was made as a 0.1 mL solution into the jugular vein.

All animals were sacrificed by guillotine 10 minutes after final test injection (see Table 3). Trunk blood for the determination of blood GH levels was collected following decapitation. After allowing the blood to clot, it was centrifuged and the serum was separated from the clot. Serum was kept frozen until the day of sampling for radioimmunoassay (RIA) determination of growth hormone levels according to the following procedure, as developed by the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK).

Reagents are generally added to the RIA analysis tubes at a single sitting, at refrigerator temperature (about 4°C) in the following sequence:

- (a) buffer,
- (b) "cold" (i.e., non-radioactive) standard or unknown serum sample to be analyzed,
- (c) radio-iodinated growth hormone antigen, and
- (d) growth hormone antiserum.

Reagent addition is generally carried out so that there is achieved a final RIA tube dilution of about 1:30,000 (antiserum to total liquid volume; vol:vol).

The mixed reagents are then typically incubated at room temperature (about 25°C) for about 24 hours prior to addition of a second antibody (e.g., goat or rabbit anti-monkey gamma globulin serum) which binds to and causes precipitation of the complexed growth hormone antiserum. Precipitated contents of the RIA tubes are then analyzed for the number of counts in a specified period of time in a gamma scintillation counter. A standard curve is prepared by plotting number of radioactive counts versus growth hormone (GH) level. GH levels of unknown are then determined by reference to the standard curve.

- 32 -

Serum GH was measured by RIA with reagents provided by the National Hormone and Pituitary Program.

Serum levels in Tables 3 and 4 are recorded in ng/mL in terms of the rat GH standard of 0.61 International Units/mg (IU/mg). Data is recorded as the mean \pm standard error of the mean (SEM). Statistical analysis was performed with Student's t-test. In Table 3, the results shown are the average of studies with six rats.

Example 3

10 Synthesis of Aib-DTrp-DPro-diisobutylamide (YL-156)

(1) Synthesis of DPro-Diisobutylamide (1):

1 mmol of Boc-DPro (Boc=tert-Butoxycarbonyl group) was dissolved in 30 ml dry CH_2Cl_2 in a 100 ml round bottom flask, with 1 mmol of 1-hydroxybenzotriazole added while stirring under N_2 atmosphere in an ice-bath, then 1.05 mmol of 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide HCl was added in 10 ml dry CH_2Cl_2 at a fast drop rate and the reaction mixture was stirred for 1 hour at 0°C . 1.1 mmol of diisobutylamine in 10 ml of CH_2Cl_2 was added dropwise and stirring was continued for a further 18 h at ambient temperature. The reaction mixture was washed with 20 ml of 20% aqueous citric acid, 20 ml of saturated aqueous NaHCO_3 , and 20 ml of saturated aqueous sodium chloride. The organic layer was separated and dried over anhydrous magnesium sulfate, filtered and concentrated in vacuum. Further purification was done by flash column chromatography (SiO_2 , $\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of Boc-DPro-diisobutylamide.

25 Under N_2 atmosphere, the Boc-DPro-diisobutylamide was dissolved in 25 ml of CH_2Cl_2 and 1- ml of trifluoroacetic acid was added while being stirred. The reaction mixture was stirred for 30 min. Volatiles were removed under vacuum and the residue was dissolved in 30 ml of CH_2Cl_2 and washed with 10 ml saturated NaHCO_3 aqueous solution. The organic layer was removed and the aqueous layer was extracted with CH_2Cl_2 (3x10 ml). The organic layer was dried over anhydrous sodium sulfate and filtered and the solvent was removed in vacuum. The residue was further purified by column chromatography (SiO_2 , $\text{CHCl}_3/\text{MeOH}$, 85:15) to afford 0.73 mmol

- 33 -

(73%) of compound (1) which was characterized by TLC on mass spectra, $M^+=225.1$.

(2) Synthesis of DTrp-DPro-diisobutylamide (2):

In a 100 ml round bottom flask, 0.70 mmol of Boc-DTrp was dissolved
5 in 25 ml dry CH_2Cl_2 and 0.70 mmol of 1-hydroxybenzotriazole was added
while stirring under N_2 atmosphere in an ice-bath then 0.75 mmol of 1-
ethyl-3-(3'-dimethylaminopropyl) carbodiimide HCl was added in 15 ml dry
 CH_2Cl_2 at a fast drop rate and the reaction mixture stirred for 1 hour at 0°C .
0.71 mmol of (1) in 20 ml of CH_2Cl_2 was added dropwise and stirring was
10 continued for a further 18 h at ambient temperature. The reaction mixture
was washed with 20 ml of 20% citric acid aqueous solution, 20 ml of
saturated NaHCO_3 aqueous solution, and 20 ml of saturated sodium
chloride aqueous solution. The organic layer was separated and dried over
anhydrous magnesium sulfate, filters and concentrated by vacuum. Further
15 purification was done by flash column chromatography ($\text{CHCl}_3/\text{MeOH}$, 95:5)
to afford white solid of Boc-DTrp-D-diisobutylamide.

Under N_2 atmosphere, the Boc-DTrp-DPro-diisobutylamide was
dissolved in 25 ml of CH_2Cl_2 , 1 ml of methylsulfide and 0.5 ml of 1,2-
ethanedithiol was added as scavenger in suppressing the indole alkylation of
20 tryptophane. 10 ml of trifluoroacetic acid was added dropwise while being
stirred. The reaction mixture was stirred for 30 min. Volatiles were removed
under vacuum and the residue was dissolved in 30 ml of CH_2Cl_2 and washed
with 10 ml saturated NaHCO_3 aqueous solution. The organic layer was dried
over anhydrous sodium sulfate and filtered and the solvents were removed in
25 vacuum. The residue was further purified by column chromatography (SiO_2 ,
 $\text{CHCl}_2/\text{MeOH}$, 85:15) to afford 0.55 mmol (78.5%) of compound (2) which
was characterized by TLC and mass spectra, $M^+=411.5$.

(3) Synthesis of Aib-DTrp-DPro-diisobutylamide (YL-156):

In a 100 ml round bottom flask, 0.50 mmol of Boc-Aib (Aib= α -
30 aminoisobutyric acid) was dissolved in 30 ml dry CH_2Cl_2 and then 0.51
mmol of 1-hydroxybenzotriazole was added while stirring under N_2
atmosphere in an ice-bath, 0.55 mmol of 1-ethyl-3-(3'-dimethylaminopropyl)
carbodiimide HCl was added in 20ml dry CH_2Cl_2 at a fast drop rate and the
reaction was stirred for 1 hour at 0°C . 0.51 mmol of (2) in 15 ml of CH_2Cl_2

- 34 -

was added dropwise and stirring was continued for a further 18 h at ambient temperature. The reaction mixture was washed with 20 ml of 20% citric acid aqueous solution, 20 ml of saturated NaCHO_3 aqueous solution, and 20 ml of saturated sodium chloride aqueous solution. The organic layer
5 was separated and dried over anhydrous magnesium sulfate, filtered and concentrated in vacuum. Further purification was done by flash column chromatography ($\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of Boc-Aib-DTrp-DPro-diisobutylamide.

Under N_2 atmosphere, the Boc-Aib-DTrp-DPro-diisobutylamide was
10 dissolved in 30 ml of CH_2Cl_2 , 1 ml of methylsulfide and 0.5 ml of 1,2-ethanedithiol were added as scavengers to suppress the indole alkylation of tryptophan. 10 ml of trifluoroacetic acid was added dropwise while being stirred. The reaction mixture was stirred for 30 min. Volatiles were removed under vacuum and the residue was dissolved in 30 ml of CH_2Cl_2 and washed
15 with 10 ml saturated NaHCO_3 aqueous solution. The organic layer was removed and the aqueous layer was extracted with CH_2Cl_2 (3x10 ml). The organic layer was dried over anhydrous sodium sulfate, and filtered and the solvents were removed in vacuum. The residue was further purified by column chromatography (SiO_2 , $\text{CHCl}_3/\text{MeOH}$, 85:15) to afford 0.43 mmol
20 (86.2%) of compound (YL-156) which was characterized by TLC and mass spectra $M^+=497.6$.

Example 4

Synthesis of inip-D α Nal-DTrp-Phe-2-aminoethylamide (YL-105)

25 3.5 g of Wang resin with the peptide attached was supplied by Research Genetics Laboratory. It was added to a 100 ml round-bottom flask and then sequentially 40 ml of dry CH_2Cl_2 , 4 ml of methanol and 2 ml of 1,2-diaminoethane were added while stirring under N_2 atmosphere. The reaction mixture was stirred for 72 hours at RT. The reaction mixture was filtered
30 and the resin was washed with 20 ml of dry CH_2Cl_2 , 20 ml of methanol. The solid resin was discarded. The organic solvent was removed by vacuum. The solid residue was further purified by flash column chromatography (SiO_2 , $\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of YL-105.

- 35 -

Further purification was performed by preparative HPLC. Molecular weight was determined by MS.

Example 5

5 Synthesis of (N-2-hydroxyethyl)-Aib-DTrp-DPro-diisobutylamide (YL-185) (Reductive Alkylation)

1 mmol of YL-156 (α AibDTrpDPro-diisobutylamide) was dissolved in 40 ml dry methanol in a 100 ml round-bottom flask and 1.5 mmol of NaBH₄ in THF was added while stirring under N₂ atmosphere. The solution was
10 acidified by adding trifluoroacetic acid in methanol to adjust the pH to 6.5. Then 1.15 mmol of ethylaldehyde was added in 10 ml dry methanol and the reaction mixture was stirred for 16 hours at RT. The solvent was removed by vacuum. The remaining residue was dissolved in 30 ml CH₂Cl₂ and washed with 20 ml of saturated aqueous NaHCO₃. The organic layer was
15 separated and dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuum. Further purification was done by flash column chromatography (SiO₂, CHCl₃/MeOH, 95:5) to afford white solid of YL-185.

Further purification was performed by preparative HPLC. The molecular weight was determined by MS.

20

Example 6

Synthesis of (N-isobutyl)Aib-DTrp-DPro-diisobutylamide (YL-194) (Hoffman Alkylation)

1 mmol of YL-156 (α AibDTrpDPro-diisobutylamide) was dissolved in
25 40 ml dry CH₂Cl₂ in a 100 ml round-bottom flask. 2 mmol of K₂CO₃ was then added while stirring under N₂ atmosphere. 1.15 mmol of 1-bromo-2-methylpropane was added in 10 ml dry CH₂Cl₂ and the reaction mixture stirred for 72 hours at RT. The reaction mixture was washed with 20 ml of saturated aqueous NaHCO₃ and 20 ml of saturated aqueous sodium
30 chloride. The organic layer was separated and dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. Further purification was done by flash column chromatography (SiO₂, CHCl₃/MeOH, 95:5) to afford white solid of YL-194.

- 36 -

Further purification was performed by preparative HPLC. Molecular weight was determined by MS.

Example 7

Synthesis of Aib-DTrp-DTrp-Phe-Arg-5-aminopentylamide (YL-174)

0.7 mmol of Fmoc-Aib-DTrp-DTrp-Phe-ArgCOOH was synthesized by Research Genetics Laboratory by the solid phase method and added to a 100 ml round-bottom flask with 40 ml of dry CH_2Cl_2 . 0.70 mmol of 1-hydroxybenzotriazole was added while stirring under N_2 atmosphere in an ice-bath and subsequently 0.75 mmol of 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide HCl was added in 15 ml dry CH_2Cl_2 at a fast drop rate. The reaction mixture was stirred for 1 hour at 0°C . 10 mmol of 1,5-diaminopentane in 20 ml of CH_2Cl_2 was added quickly and stirring was continued for an additional 18 h at ambient temperature. The reaction mixture was washed with 20 ml of saturated NaHCO_3 aqueous solution and 10 ml of saturated sodium chloride aqueous solution. The organic layer was separated and dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. Further purification was done by flash column chromatography ($\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of Fmoc-Aib-DTrp-DTrp-Phe-ArgCONH $(\text{CH}_2)_5\text{NH}_2$. This compound was dissolved in 20 ml of CH_2Cl_2 and under N_2 atmosphere 10 ml of piperidine was added. The solution was stirred for another 4 hours. The solvent was removed by vacuum and the residue was further purified by flash column chromatography ($\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of YL-174.

Further purification was performed by preparative HPLC. Molecular weight was determined by MS.

Example 8

Synthesis of Aib-DTrp-DPro-3-methylpiperidinamide (YL-111)

(Aib-DTrp-DPro-R, R=various of amine end groups, for example piperidine, 3-methyl piperidine, etc. All other Aib-DTrp-DPro-R compounds can be synthesized by using the same procedure):

(1) Synthesis of DPro-3-methylpiperidinamide (methylpiperidine) (1):

- 37 -

1 mmol of Boc-DPro (Boc=tert-Butoxycarbonyl group) was dissolved in 30 ml dry CH₂Cl₂ in a 100 ml round-bottom flask, 1 mmol of 1-hydroxybenzotriazole added while stirring under N₂ atmosphere in an ice-bath, 1.05 mmol of 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide HCL was added in 10 ml dry CH₂Cl₂ at a fast drop rate and the reaction mixture stirred for 1 hour at 0° C. 1.1 mmol of 3-methylpiperazine in 10 ml of CH₂Cl₂ was added dropwise and stirring was continued for an additional 18 h at ambient temperature. The reaction mixture was washed with 30 ml of 20% aqueous citric acid, 30 ml of saturated aqueous NaHCO₃, and 30 ml of saturated aqueous sodium chloride. The organic layer was separated and dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuum. Further purification was done by flash column chromatography (SiO₂, CHCl₃/MeOH, 95:5) to afford white solid of Boc-DPro-D-piperidinamide.

Under N₂ atmosphere, the Boc-DPro-3-piperidinamide was dissolved in 25 ml of CH₂Cl₂ and 10 ml of trifluoroacetic acid added while stirring. The reaction mixture was stirred for 30 min. All volatiles were removed under vacuum and the residue dissolved in 30 ml of CH₂Cl₂ and washed with 10 ml saturated NaHCO₃ aqueous solution. The organic layer was removed and the aqueous layer extracted with CH₂Cl₂ (3x10 ml). The organic layer was dried over anhydrous sodium sulfate and filtered and the solvent was removed by vacuum. The residue was further purified by column chromatography (SiO₂, CHCl₃/MeOH, 85:15) to afford 0.65 mmol (65%) of compound (1) which was characterized by TLC and mass spectra, M⁺=196.3.

(2) Synthesis of DTrp-DPro-3-methylpiperidinamide (methylpiperidine) (2):

In a 100 ml round-bottom flask, 0.63 mmol of Boc-DTrp was dissolved in 25 ml dry CH₂Cl₂ 0.66 mmol of 1-hydroxybenzotriazole was added while stirring under N₂ atmosphere in an ice-bath. 0.63 mmol of 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide HCL was added in 10 ml dry CH₂Cl₂ at a fast drop rate and the reaction mixture was washed with 20 ml of 20% citric acid aqueous solution, 20 ml of saturated NaHCO₃ aqueous solution and 20 ml of saturated sodium chloride aqueous solution. The organic layer was separated and dried over anhydrous magnesium sulfate,

- 38 -

filtered and concentrated in vacuum. Further purification was done by flash column chromatography ($\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of Boc-DTrp-DPro-3-piperidinamide.

Under N_2 atmosphere, the Boc-DTrp-DPro-3-piperidinamide was dissolved in 25 ml of CH_2Cl_2 and 10 ml of trifluoroacetic acid was added while being stirred. The reaction mixture was stirred for 30 min. All volatiles were removed under vacuum and the residue was dissolved in 30 ml of CH_2Cl_2 and washed with 10 ml saturated NaHCO_3 aqueous solution. The organic layer was removed and the aqueous layer was extracted with CH_2Cl_2 (3x10 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent removed in vacuum. The residue was further purified by column chromatography (SiO_2 , $\text{CHCl}_3/\text{MeOH}$, 85:15) to afford 0.43 mmol (68.3%) of compound (2) which was characterized by TLC and mass spectra, $M^+=382.46$.

(3) Synthesis of Aib-DTrp-DPro-3-methylpiperidinamide (methylpiperidine) (YL-111):

In a 50 ml round bottom flask, 0.33 mmol of Boc-Aib was dissolved in 20 ml dry CH_2Cl_2 and then 0.31 mmol of 1-hydroxybenzotriazole was added while stirring under N_2 atmosphere in an ice-bath. 0.35 mmol of 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide HCL was added in 10 ml dry CH_2Cl_2 at a fast drop rate and the reaction mixture was stirred for 1 hour at 0°C . 0.30 mmol of (2) in 15 ml of CH_2Cl_2 was added dropwise and stirring was continued for an additional 18 h at ambient temperature. The reaction mixture was washed with 20 ml of 20% citric acid aqueous solution, 20 ml of saturated NaHCO_3 aqueous solution and 20 ml of saturated sodium chloride aqueous solution. The organic layer was separated and dried over anhydrous magnesium sulfate, filtered and concentrated in vacuum. Further purification was done by flash column chromatography ($\text{CHCl}_3/\text{MeOH}$, 95:5) to afford white solid of Boc-Aib-DTrp-DPro-3-piperidinamide.

Under N_2 atmosphere, the Boc-Aib-DTrp-DPro-3-piperidinamide was dissolved in 25 ml of CH_2Cl_2 and 10 ml of trifluoroacetic acid was added while being stirred. The reaction mixture was stirred for 30 min. All volatiles were removed under vacuum and the residue was dissolved in 30 ml of CH_2Cl_2

and washed with 10 ml saturated NaCHO₃ aqueous solution. The organic layer was removed and the aqueous layer was extracted with CH₂Cl₂ (3x10 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent removed in vacuum. The residue was further purified by column chromatography (SiO₂, CHCl₃/MeOH, 85:15) to afford 0.28 mmol (84.8%) of compound (YL-111) which was characterized by TLC and mass spectra M⁺=468.6.

Biological Activity

In vitro and *in vivo* activity of certain compounds were determined in rats and adult beagle dogs (*in vivo* activity only). The results are described in Tables 3, 4, 5, 6 and 7 below.

The GHRP-2 (reference standard) has the structure DAla-DβNal-Ala-Trp-DPhe-Lys-NH₂ (Chen and Clarke, *J. Neuroend.* 7: 179 (1995)).

Table 3: *In Vitro* Release of Growth Hormone in Rat

Compound R ¹ -N ₂ -Aib DTrpX* Where X is:	control	GHRP-2 .001	.0001	.0003	.001	.003	.01	.03	.1	.3	GH ng/ ml 1
DPro NH ₂	752	1525	922	1102	997	1250	1535	1550	1716		
DPro-diiso- butylamide	523	1307					1322	1529	1427	1155	1124
R ¹ =N-2- OHethyl DPro-diiso- butylamide	341	1427	---	---	452	326	526	820	1163	1217	
R ¹ =N ₂ N-di- 2-OHethyl/ DPro diiso- butylamide	341	1427	---	---	433	395	446	592	905	1206	
R ¹ =N- ethyl/DPro diisobutyl- amide	510	1413	---	---	523	461	779	742	1079	1292	
R ¹ =Nentyl/ DPro diisobutyl- amide	341	1427	---	---	570	698	982	1307	1467	1387	
DPro- dipropyl- amide	543	1065	554	578	554	630	823	908	925		
DPro- butylamide	523	1307	512	647	833	995	1253	1612			
DPro- pentylamide	622	1290				569	830	1172	1184	1335	1451
DPro- dipentyl- amide	523	1307			1348	1561	1287	1021	1451		

- 40 -

Compound R ¹ -N ₂ -Aib DTrpX* Where X is:	control	GHRP-2 .001	.0001	.0003	.001	.003	.01	.03	.1	.3	GH ng/ ml 1
DPro- piperidine- 3- methylbenz yl ether	389	821	529	553	721	728	886	978			
N,N- diethylnipe- cotamide	397	593	418	395	489	536	642				
-N- piperazine methyl- sulfonamide	553	1167		672	675	856	1049				
DPro- diethylamid e	389	821	375	368	481	587	802	912			
DPro-m- methylpiper -idine	308	1052	434	458	633	837	968				
DPro-3,3- diphenyl- propylamide	466	1126			926	1118	1169	1177	1283		
DPro-4- piperidino- piperidin- amide	376	1125		419	451	540	808				
DPro-4- phenylpiper -idinamide	455	1520	624	777	1034	1186	1533	1772			
DPro-N- methyl- piperiazine	389	821	467	532	573	605	816	909			
DPro-2- morpholino- ethylamine	397	593	394	413	433	485	548				
DPro- spiroindole methyl- sulfonamide	385	915	440	512	691	819	956	922	1057		
DPro- pyrrolidine amide	614	1288	714	873	1149	1241					
DPro- indoline amide	486	1344			836	1127	1283	1235	1258	1220	1327
DPro-3- piperidine methanol amide	486	1344			1008	1199	1209	1348	1626	1567	
DPro-tropin amide	510	1220			542	797	1001	1124	1234		
DTrpPhe- Arg-5- amino pentamide	752	1525	1228	1416	1712	1648	1621				

* Unless otherwise stated, R¹ is H

Table 4: *In Vivo* Release of Growth Hormone in Rat

Compound R ¹ -N ₂ -AibDTrpX* Where X is:	control	GHRP-2							GH ng/ml 100
		.1	.1	.3	1	3	10	30	
DPro NH ₂	223	1580	326	433	1159	2217	3155		
DPro-diisobutylamide	111	1066			642	1524	1837	2307	2913
R ¹ =N-2-OHethyl/ DPro-diiso- butylamide	92	2051	---	---	---	156	259	451	---
R ¹ =N,N-di-2- OHethyl/ DPro-diiso- butylamide	96	799	---	---	---		124	208	543
R ¹ =N -ethyl/ DPro-diiso- butylamide	92	2051	---	---	189	177	268	374	---
R ¹ =N -pentyl/ DPro-diiso- butylamide	92	2051	---	---	124	398	371	789	---
DPro-dipropylamide	91	1082	92	220	305	579	1646	2089	
DPro-butylamide	111	1066			196	329	647	2005	1596
DPro-pentylamide	170	1289			310	581	820	1660	2280
DPro-dipentylamide	128	1071	87	182	322	355	632	482	1206
DPro-piperidine-3- methyl-benzyl ether	150	1235			669	1725	2319		
N,N-diethylnipecot- amide	117	579		221	928	2070	2896	2186	
-N-piperazine methyl-sulfonamide	113	942		241	933	1965	1997		
DPro-diethylamide	128	919			448	766	1719	2465	3088
DPro-m- methylpiperidine	93	445				832	1557	1570	1762
DPro-3,3-diphenyl- propylamide	114	1106	141	147	138	249	383	624	
DPro-4-piperidino- piperidin-amide	150	1235				378	1318	2403	
DPro-4- phenylpiperidin- amide	111	568		112		238		499	
DPro-N-methyl- piperazine	128	919	218	425	1974	2314			
DPro-2-morpholino- ethylamine	111	568				900	1585	2195	
DPro-spiroindole methyl-sulfonamide	120	586				192	485	861	1177
DPro-pyrrolidine amide	98	1227				1024	2116	2381	
DPro-indoline amide	69	1279			142	317	269	885	
DPro-3-piperidine methanol amide	91	1082	155	668	1483	2616	2711		
DPro-tropin amide	73	1814		114	87	183	362	383	769
DTrpPhe-Arg-5- amino pentamide	109	1718	262 8	274 0	2272	2929			

* Unless otherwise stated, R¹ is H

Table 5: *In Vivo* Release of Growth Hormone in Adult Beagle Dogs

Compound R ¹ -N ₂ -AibDTrpX* Where X is:	oral dose (mg/kg)	0	0.5	1	2	3	4	5	6	7	Time (hr) 8
DPro NH ₂	4	0.7	38	14	9.5	13	7.1	3.3	4	2.5	1.3
	4	0.8	54	30	15	12	4.8	4.2	3.4	1	0.8
DPro-diisobutylamide	4	0.8	27	9.4	14	22	22	21	11	6.9	5.4
	4	1.4	141	50	74	15	7.5	4	4.4	5.7	2.3
	2	0.6	54	30	22	15	7	4.6	4.8	2.7	1.8
	1	2.6	85	30	16	7.7	6	0.9	2.5	2.5	1.6
	1	<0.5	128	50	24	24	5.6	6.1	2.9	2.2	-
	1	1.5	89	59	30	11	7	6.2	5.2	3.7	3.2
R ¹ =N-2-OHethyl/ DPro-diisobutyl- amide	1	3.8	102	26	25	10	6.1	5.6	4.0	5.2	5.0
	1	1	62	30	19	5.6	3.8	2.0	2.5	2.0	1.6
	1										
R ¹ =N ₂ -di-2- OHethyl/ DPro- diisobutylamide	1										
R ¹ =N -ethyl/ DPro-diisobutyl- amide	4	1.3	100	29	20	9.4	3.9	2.2	2.4	1.5	5.6
	1	1.1	17	4.4	1.2	1.5	1.4	1.1	1.2	1.4	1.2
R ¹ =N -pentyl/ DPro-diisobutyl- amide	1										
DPro-dipropylamide	4	3.2	112	52	29	25	13	6.1	3.6	2.9	2.5
	1	0.6	27	19	5.6	1.6	1.6	0.6	1.4	0.8	0.8
DPro-butylamide	4	1.1	92	43	26	53	14	5.4	3.5	3.9	1.3
	2	1.8	60	40	13	3.8	3.7	2.2	2.6	2.4	1.7
DPro-pentylamide	4	1	72	12	11	6	4.9	3.5	2.5	1.9	1.4
DPro-dipentylamide	4	2.3	53	20	1.3	15	15	8.9	9.2	6.6	4.3
	4	3.7	32	11	8.4	7.2	3.6	3.5	2.3	2.7	<0.1
	4	2.9	11	11	15	3	3.3	2.5	2.7	2.3	2
DPro-piperidine-3- methyl-benzyl ether	4	2	>12	59	63	28	11	6.7	4.2	4.1	1.8
	4	0.8	8	28	27	11	14	14	11	4.7	6.8
	2	3.2	127	42	63	45	13	5.5	4.5	3.4	3.2
	2	3.6	169	39	23	6.3	4.5	1.7	2.7	2.3	1.9
	F0.5iv	2.9	112	78	27	9.3	4.5	4.1	2.9	4.1	4.1
			81								
N,N-diethylnipe- cotamide	4	1.7	57	13.	5.3	5.5	3.4	3.1	1.9	2	1.7
	4	0.9	43	8	2	2.1	0.8	0.9	2.1	6.9	0.9
	4F	2.7	6.3	7.3	3.7	2.2	0.9	10.	3.6	3.5	3.5
				3.5				1			
-N-piperazine methyl-sulfonamide	4	2.1	57	12.	8.7	3.8	1.7	2.2	1.6	6.3	3.2
				5							
DPro-diethylamide	4	2.4	56	38	29	28	16	9.1	6.2	3.9	2.8
	4	1.7	134	89	105	86	16	7.1	5.1	4.5	3.2
	F0.5iv	1.6	60	18	6	3.7	2.5	2	1.9	1.7	2.5
DPro-m- methylpiperidine	4	1	54	-	50	52	20	27	8.1	9.6	1.7
	4F	1.4	72	84	18	4.7	3.5	1.4	1.1	1.6	1.5
	4	2.1	118	55	54	53	34	13	11	11	6.4
	2	1.2	128	59	29	12	8.9	3.6	3	3	1.7
	1	1.6	53	19	15	9.6	3.1	2.2	1.5	2.2	1
	1	2	63	32	17	13	12	1.5	2.4	3	2.2
DPro-3,3-diphenyl- propylamide	4	1.6	119	54	17	16	10	5.6	4.2	3.3	2.7
	4	2.2	54	12	8.6	7.4	13	5.9	3.4	3	ns
DPro-N-methyl-l- piperazine	4	1	100	22	8.3	7.9	4.8	2.6	2.9	2.3	1.8
	0.5iv	0.8	41	31	7	3.3	2.6	1.5	2.4	0.9	1.1
DPro-spiroindole methyl-sulfonamide	4	1.5	<0.	5.5	1.6	1.5	2.2	4.7	1.7	1.6	0.9
			5								
DPro-pyrrolidine amide	4	2.3	104	28	18	7.1	5.1	3.2	2.7	2.2	2.3
	4	2.1	63	32	45	30	11	6	4.9	4.1	3.6

- 43 -

Compound R ¹ -N ₂ -AibDTrpX* Where X is:	oral dose (mg/kg)	0	0.5	1	2	3	4	5	6	7	Time (hr) 8
DPro-indole amide	4	1.2	7	7.5	5.8	4.7	3.1	2.8	2.5	2	1.6
DPro-3-piperidine methanol amide	4	2.3	55	14	7.5	2.9	3.8	3.4	2.4	2.3	1.8
DPro-tropinamide	4	1.9	72	47	5.5	3.8	3.8	2.8	2.5	2.2	2.2
DTrpPhe-Arg-5- amino pentamide	2 1	3.1 2.5	63 38	20 8.5	6.8 2.8	3.9 2.3	2.9 1.4	3.3 1.7	3.1 2.1	3.3 2	3 0.8

* Unless otherwise stated, R¹ is H

Table 6: *In Vivo* * Release of GH Rat

#	Compound iv	control	GHRP-2	GH ng/ml							
				.1	.03	.1	.3	1	3	10	30
861	inipD α NalDTrpNH ₂	145	1251					485	2197	2380	
1473	inipD α NalDValNH ₂	145	1251					225		225	
1466	α AibDTrpDValNH ₂	145	1251					124		418	
1415	α AibDTrpDProDSerNH ₂	120	1465				820	1658	2306	2896	
1417	α AibDTrpDProDArgNH ₂	120	1465				1362		2161	2057	
1246	α AibDTrpDProDPheNH ₂	92	566			203	594	1901	2339		
1248	α AibDTrpDProDTrpNH ₂	145	1343				229		1814		
1460	α AibDTrpDValDValNH ₂	145	1343					104		240	
1461	α AibDValDProDValNH ₂	145	1343					160		261	
1464	α AibDValDValDValNH ₂	145	1343					96		197	
1468	α AibDTrpDProDLysNH ₂	145	1343				157		791		
1462	α AibDProDProDValNH ₂	145	1251					218		185	
1472	inipD α NalDTrpDValNH ₂	145	1251			174	142	154	1019		
1489	α AibDTrpDProIleNH ₂	135	1734			445	355	1884			
1476	α AbuD α NalDTrpDlleNH ₂	166	1175			97	111	152	152		
1495	inipD α NalDTrpDProIleNH ₂	166	1175					824		1971	
1496	inipD α NalDTrpPhelleNH ₂	166	1175					1638		2055	
1471	inipD α NalDTrpDValArgNH ₂	145	1251			98	184	843			

#	Compound iv	control	GHRP-2	GH ng/ml									
				.1	.01	.03	.1	.3	1	3	10	30	
1469	α AibDTripDProDValDValNH ₂	164	411					783	2450	1975			
1480	α AibDTripDProDProDProDPalNH ₂	78	990				245	622	2775				
1481	α AibDTripDProDValArgDProNH ₂	164	411				1703	2145	2278	2511			
1484	α AibDTripDProDlleDArgNH ₂	105	750		317	562	1863	2224	2446				
1475	$\alpha\gamma$ AbuDTrpDTrpDlleNH ₂	101	369				123	125	113				
1486	inipD α NalDTrpPheDValNH ₂	101	369				203	352	1009				
1488	α AibDTrpDProValNH ₂	105	750				323	644	1725				
1465	α AibDTrpDlleDlleNH ₂	105	750						160				
1500	α AibDTrpDProLeuNH ₂	225	1429					1831	2623				
1492	α AibDTrpDProThrNH ₂	164	411				125	176	1031				
1497	DHisDTrpDProDValArgNH ₂	164	411					154	181	235	601		
1451	DHisDTrpDProDThrNH ₂	128	811(.03)					1380	2450	3133	2731		
		135	1734				898						
1452	α AibDTrpDProDlleNH ₂	105	750				1028	1837	2138				
1474	α AibDTrpDPheDValNH ₂	101	369				146	117	184				
1478	α AibDTrpDProDValDArgNH ₂	124	1251				1420	2304	2245				
		135	1734				1177						
1293	α AibDTrpDProDAlaNH ₂	157	1171				416	341	1682	3295			
1226	α AibDTrpDProDProNH ₂	124	1072						2129				
1136	α AibDTrpDProArgNH ₂	120	1465				297	670	1769	2644			

#	Compound iv	control	GHRP-2	GH ng/ml									
				.01	.03	.1	.3	1	3	10	30		
1251	α AibDTrpDProDValNH ₂	188	439		228	832	1581	2405					
		120	1465			1584	2360	2181	3250				
1325		inipD α NalDTrpDProNH ₂	120	1465					409	1203	2475		
1518	α AibD α NalDProDValDArgNH ₂	99	1179		298	722	1695	2279					
1520	α AibD α NalDProDlleDArgNH ₂	99	1179		325	640	1481	2497					
1487	α AibDTrpDProDProDLysNH ₂	135	1734			171	676	1562					
1506	α AibHisD β NalDPhelysNH ₂	136	1169			137	244	1416					
1507	α AibHisDTrpDProDValNH ₂	136	1169			129	94	118					
1508	α AibHisDTrpDProDlleNH ₂	136	1169			132	137	123					
1509	α AibHisDTrpDProValArgNH ₂	136	1169			157	138	123					
1510	α AibHisDTrpDProDValArgNH ₂	136	1169			145	133	246					
1511	α AibD β NalDProDValNH ₂	136	1169			171	246	486					
1512	α AibD α NalDProDValNH ₂	136	1169			143	141	611					
1523	α AibDTrpDProDThrArgNH ₂	99	1179		1336	2219	2167	2781					
1524	α AibDTrpDProDNIleArgNH ₂	99	1179		1425	1952	2334	2164					
		17	1395	298	1151	2593	2275	2672					
1525	α AibDTrpDProDNValArgNH ₂	99	1179		1397	2061	2285	2250					
		117	1395	146	580	1380	2047	1853					
1490	α AibDTrpDProlleArgNH ₂	135	1734			173	202	179					
		105	750			137		397					

#	Compound iv	control	GHRP-2	GH ng/ml									
				.01	.03	.1	.3	1	3	10	30		
1479	α AibDTrpDProDProArgNH ₂	101	369			2081	2566	2269					
1493	α AibDTrpDProDProArgNH ₂	225	1429				96	152	431				
1483	α AibDTrpDProDProDArgNH ₂	135	1734			333		1838					
1485	α AibDTrpDProDlleArgNH ₂	78	990	969	1472	1981	2073	3289					
1407	α AibDTrpDProDPhcDSerNH ₂	138	1004										
1137	α AibDTrpDProDPhcArgNH ₂	120	1465			225	175	149		389	1365		
1470	α AibDTrpDProDValArgNH ₂	145	1251	600	1576	2647	2002	3414					
803	SarDTrpDTrpPheArgNH ₂	120	1465				778	1894	2498				
1532	α AibD α NalDProDProArgNH ₂	124	1012					1989					
1533	α AibD α NalDProDNValArgNH ₂	124	1012					1910					
1519	α AibD α NalDProDlleArgNH ₂	99	179		1641	1491	2354	2370					
1521	α AibD α NalDProDVallLysNH ₂	99	179		573	1372	2008	2355					
1530	α AibD α NalDProDThrArgNH ₂	124	1012	388	317	1035	2873	2611					
1531	α AibD β NalDProDThrArgNH ₂	124	1012					2303					
1513	α AibD β NalDProDValArgNH ₂	136	1169			611	3230	3322					
1514	α AibD α NalDProDValArgNH ₂	136	1169			1508	2710	2562					
		117	1395	404	687	1624	2516	2507					
1534	α AibDTrpDProDNleNH ₂	120	1132			436	718	1968					
1535	α AibDTrpDProDNValNH ₂	120	1132			228	614	1710					

#	Compound iv	control	GHRP-2	GH ng/ml							
				.01	.03	.1	.3	1	3	10	30
	α AibDTrpDProDlle-X		.1								
TJ 39	2-aminoethylamide	124	1012			1416	1739	2742	2931		
TJ 49	5-aminopentylamide	120	1132			1262	2822	2501	2426		
TJ 53	3-aminopropylamide	120	1132			575	1697	2603	1901		
	α AibDTrpDProDVal-X										
TJ 45	2-aminoethylamide	117	1395			813	1958	1736			
TJ 5	dimethylamide	135	1734			247	836	1362	1805		
TJ 8	diethylamide	135	1734			232	255	366	1157		
	α AibDTrpDProDPro-X										
TJ 28	2-aminoethylamide	73	766			151	339	558	920	1999	
353	D β NaIAlaTrpDPheLysGlnGlyNH ₂	90	1542			879	1307	1268	2729		
359	DAlaDTrpAlaTrpDPheLysValGlyNH ₂	151				2553	3653	2530			
		90	1542		452	1763	3364	3003			
371	DAlaD β NaIAlaTrpDPheLysGlnGlyGlyNH ₂	157	983	535	1834	2176	2116	3995			
356	DAlaDTrpAlaTrpDPheLysHisGlyNH ₂	90	1542			1252	2811	1886			

Table 7: *In Vivo** Release of GH in Adult Beagle Dogs

#	Compound	oral dose mg/kg	Time (hr)									
			0	0.5	1	2	3	4	5	6	7	8
			Canine GH ng/ml									
	α AibDTrpDProDlleX											
TJ49	5-aminopentylamide	1	5.4	123	27	21	20	5.6	2.3	1.2	0.8	1.4
		1	3.8	116	20	5.7	13	19	3.3	1.1	1	1.1
TJ53	3-aminopropylamide	1	6	44	19	22	7.8	6.4	6.7	5.4	6.4	6.9
		1	5.9	91	32	19	7.3	6.2	13.	6.6	4.7	5.6
									2			
TJ39	2-aminoethylamide	1	5.7	31	11	10	10	4	4.4	3.8	5.1	3.4
		1	3.4	99	21	19	14	9.1	4.6	4	4.2	3.8
TJ66	4-aminobutylamide	1	1.8	100	20	19	4	2.8	2.7	2.1	3.4	2.8
	α AibDTrpDProDValX											
TJ6	N-dimethylamide	1	5.1	9.5	5.4	5.6	5.5	6	6.2	5	6.4	3.8
TJ8	N-diethylamide	1	20	8.7	5	15	6	4.4	4.8	5.1	4.3	4.4
TJ45	2-aminoethylamide	1	6.4	97	26	24	8	3	6	12	9	8
		1	7.6	52	24	21	13	9	8	9	8	8
	α AibDTrpDProDValX											
TJ01	5-aminopentylamide	1	3.7	41	12	5.3	4.4	4.1	3.7	3.5	4.8	4.1
		1	2.3	91	17	26	7.6	4.2	3.5	3	3.8	2.7

#	Compound	oral dose mg/kg	Time (hr)										
			0	0.5	1	2	3	4	5	6	7	8	
			Canine GH ng/ml										
	α AibDTrpDProDNIeX												
TJ59	5-aminopentylamide	1	6.4	54	16	13	5	5	5.1	6.9	6.4	5.9	
		1	6.7	112	19	14	13	7.4	6.6	7.1	6.4	5.4	
1476	α AibDTrpDProDValDArgNH ₂	2	3.2	42	31	13	25	5	3.1	4.1	2.6	1.7	
1513	α AibD β NalDProDValArgNH ₂	1	6.6	128	38	47	35	25	8.7	6.5	6.9	7.2	
		1	5.3	125	22	8.7	6.3	5	3.6	3.6	6.7	3.6	
1514	α AibD α NalDProDValArgNH ₂	1	3.5	31	10	5.8	5.4	4.2	3.2	3.8	3.4	3.6	
		1	3.5	126	24	31	14	7.3	3.5	4.8	3.1	4.9	
1519	α AibD α NalDProDlleArgNH ₂	1	6.8	72	28	21	13	6.5	5.5	4.4	6.9	5.2	
1521	α AibD α NalDProDValLysNH ₂	1	3.7	111	39	61	29	14	8.2	4	4.4	4.7	
973	inipD α NalD β NalPheArgNH ₂	2	3.1	13	4.2	3.3	2.5	2.1	2.9	2.3	2.9	2.4	
1536	α AibDTrpDProDlleArgGlyNH ₂	0.5	1.5	93	23	29	8.2	6.5	5.5	4.3	4.3	2.9	
1537	α AibDTrpDProDNIeArgGlyNH ₂	0.5	3.7	76	12	10	2.6	3.1	2.3	2.3	2.8	2.8	
1539	α AibDTrpDProDThrArgGlyNH ₂	0.5	1.8	86	28	85	13	7.6	4.8	2.7	2.7	2.3	
1252	α AibDTrpDProDGlnNH ₂	2	1.5	2.6	6.4	3.5	2.8	2.5	2.3	1.9	1.9	2	
869	InipD α NalDTrpPheCOOH	2	2.6	3.5	2	2.6	2.7	2.6	2.5	3.6	3.6	3.2	
		1	1.4	1.8	1.3	1.5	1.3	2.1	1.9	2.6	1.4	2.1	
956	InipD α NalDTrpValNH ₂	1	4.2	3.3	3.9	4	3.6	5.5	3.4	3.8	2.3	3.1	

#	Compound	oral dose mg/kg	Time (hr)										
			Canine GH ng/ml										
			0	0.5	1	2	3	4	5	6	7	8	
1136	α AibDTrpDProArgNH ₂	1.1	4.9	15	8.3	6.3	4.8	5.2	4.8	4.3	5.1	4.8	
		1	1.7	27	8.7	1.5	1.9	1.9	2.4	2.7	1.6	2.7	
1118	α AibDTrpDProCH α AlaNH ₂	1	6.6	3.8	2.6	2.6	2.8	2.8	1.9	2.1	2.9	2.6	
1251	α AibDTrpDProDValNH ₂	2	2.9	47	16	14	7.8	5.6	4.7	5.6	6.8	4.9	
		2	1.6	28	5.6	4.1	4.1	4	4.1	4.2	3	2.6	
		1.1	2.4	128	31	42	5.5	4.8	4.4	3.4	4.4	3.4	
1293	α AibDTrpDProDAlaNH ₂	2	4.6	11	4.9	4.9	4.6	5.5	5.9	4	4.7	4.7	
		2	2.9	15	8.9	11	4	3.8	3	2.7	3.6	2.7	
		2	3.9	14	6.2	3.8	2.7	1.9	2.9	2.4	3.4	3.1	
1452	α AibDTrpDProDlleNH ₂	2	2.5	117	23	13	4.1	3.6	5	4.3	5.2	4.7	
1451	α AibDTrpDProDThrNH ₂	2	1.4	20	4	3.9	2.7	2	1.7	2.5	2.6	1.6	
		1.6	3.3	51	22	58	7.1	5.6	4.9	4.6	4.6	4.1	
1246	α AibDTrpDProDPheNH ₂	2	1.7	29	20	9.2	3.7	2.7	1.6	1.9	2.4	1.8	
1474	α AibDTrpDPheDValNH ₂	2	3.2	2.9	2.8	2.7	2.9	2.9	2.8	2.8	4.7	2.7	
1248	α AibDTrpDProDTrpNH ₂	2	1.8	5.9	2.7	1.4	2.2	1.8	1.7	1.3	3.2	3.3	
1479	α AibDTrpDProDArgNH ₂	1.8	2	38	9.3	6.2	6.1	6	5.7	4.7	2.7	2.1	
1478	α AibDTrpDProDValDArgNH ₂	2	3.2	42	31	13	25	5	3.1	4.1	2.6	1.7	
1470	α AibDTrpDProDValArgNH ₂	2	3.6	62	26	30	30	6.8	13	14	6.5	5.4	
		2	3.4	37	32	41	13	23	9.2	8	4.9	4.1	

#	Compound	oral dose mg/kg	Time (hr)										
			0	0.5	1	2	3	4	5	6	7	8	
			Canine GH ng/ml										
1485	α AibDTrpDProDlleArgNH ₂	1	5.1	32	14	18	16	14	11	6.3	6.3	5.2	
		2	4.9	102	19	48	23	11	8	9	16	21	
		2	5.7	49	38	26	10	21	7.6	6.7	10	11	
		2	3.5	20	17	15	16	18	13	19	13	14	
		2	1.2	60	34	15	9.2		5.3		4.5	4.7	
		1	4.6	136	23	95	14	22	8.3	6.9	4.9	5.2	
		1	6.7	104	47	84	41	29	15	19	15	5.4	
		1	5.2	50	17	11	6.9	6.8	6.2	7.1	6.7	4.5	
		0.5	6	110	63	32	13	12	4.9	5	5.6	5.4	
		0.5	7.8	109	78	54	49	97	52	51	22	16	
		0.5	6.1	126	78	32	12	7.8	4.3	15	9.2	3.6	
		0.5	6.6	125	57	35	20	11	40	15	8	8	
		0.5	5.9	227	28	26	40	13	50	9	7	7	
		0.25	3.5	102	35	32	28	5.8	3.7	4.1	5	6.9	
		0.25	2.1	53	13	10		3.1	2.1	4	3.3	4.4	
		0.125	3.6	48	23	7.9	3.8	3	3.9	3	5.7	3.4	
		0.125	2.6	53	16	7.6	3.3	3.9	3.9	3.6	5.3	3.2	
		1	5.4	105	63	40	30	15	8	9.3	7.9	4	
		1	5.3	110	105	128	38	25	18	7.8	4.5	3.8	
		1523	α AibDTrpDProDThrArgNH ₂										
1524	α AibDTrpDProDNIeArgNH ₂												

#	Compound	oral dose mg/kg	Time (hr)									
			0	0.5	1	2	3	4	5	6	7	8
			Canine GH ng/ml									
		0.5	5.6	72	23	10	7.1	7.1	6.7	6.4	5.9	5.6
1525	α AibDTrpDProDnValArgNH ₂	0.5	6	99	58	26	13	7.8	6.2	6	5.7	4.6
TJ64	5-aminopentylamide	1	1.5	32	13	5.6	3.5	2.3	2.7	1.4	2.9	3.2

IN THE CLAIMS:

1. A compound having the formula



wherein A_1 is Aib, inip, ABU, β Ala, His, Sar or any of their respective D-isomers;

Y is $A_2-A_3-A_4-A_5-A_6-Z'$;

$A_2-A_3-A_4-A_5-Z'$ or $A_2-A_3-A_4-Z'$;

wherein A_2 is A_5-A_2 or A_2 ;

wherein A_5 is a spacer amino acid;

A_2 is any natural L-amino acid, Pal, or their respective D-isomers, D α Nal or D β Nal;

A_3 , A_4 and A_5 are any natural L-amino acid, Pal, α Nal, β Nal, Nle, Arg-DPro, DPCl, D or L cyclohexyl-amino acid, or any of their respective D-isomers; and

Z' is NH_2 , OH, C_1-C_{10} alkylamino, di(C_1-C_{10} alkyl) amino, amino- C_1-C_{10} alkylamino or di(amino C_1-C_{10} alkyl) amino;

and pharmaceutically acceptable salts thereof.

2. The compound of claim 1, having the formula Aib-Y.
3. The compound of claim 2, wherein Aib is α Aib.
4. The compound of claim 2, wherein the Aib residue is substituted or unsubstituted.
5. The compound of claim 4, wherein Aib is substituted and the substituents are selected from the group consisting of N- and N-, N- C_1-C_6 alkyl, halogens, N- and N-, N-2 hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl and 3-hydroxyisobutyl.
6. The compound of claim 2, wherein Aib is unsubstituted.
7. The compound of claim 1, wherein A_1 is Aib, inip or ABU.
8. The compound of claim 7, wherein A_1 is ABU and ABU is γ ABU or α,γ ABU.
9. The compound of claim 1, 2, 3, 4, 5 or 6, wherein A_2 is DTrp, D α Nal or D β Nal.
10. The compound of claim 9, wherein A_2 is DTrp.

- 55 -

11. The compound of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 wherein A₃ is DPro or DTrp;

12. The compound of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, wherein A₄ is Gly, Phe, Pro, Ile, DPro, DPhe, DPal, DLeu, DHis, DVal, DGln, Dlle, DNle, DArg, DAla, DSer, DThr, Dlle, Arg, Orn Lys, Ala, Pal, Thr, Val, Phe, DTrp, DNVal, DNle or D or L cyclohexylalanine.

13. The compound of claim 12, wherein A₄ is DSer, DArg, DPro, DTrp, DVal, Dlle, DThr, DNVal, DNle, Ile, Pro, Phe.

14. The compound of claim 13, wherein A₄ is DPro, DTrp, Dlle or DNle.

15. The compound of claim 14, wherein A₄ is DPro.

16. The compound of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 wherein A₅ is Ile, Arg, Pal, DArg, DSer, Lys or Arg-DPro or DLys.

17. The compound of claim 16, wherein A₅ is Arg, DArg, Lys or DLys.

18. The compound of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17, wherein Z' is C₁-C₁₀ alkylamino, di(C₁-C₁₀ alkyl)amino, amino-C₁-C₁₀ alkylamino or di(amino C₁-C₁₀ alkyl) amino.

19. The compound of claim 18, wherein Z' is 2-aminoethylamide, -3-aminopropylamide, -4-aminobutylamide, -5-aminopentylamide, -6-aminohexylamide, mono or dimethylamide, mono or diethylamide, mono or dipropylamide.

20. The compound of claims 1, 2 or 3 wherein Y is A₂-DPro-A₄-A₅-A₆-Z', A₂-A₃-A₄-Z' or A₂-A₃-A₄-A₅-Z'.

21. The compound of claim 20, wherein Y is A₂-DPro-A₄-Z', or A₂-DPro-A₄-A₅-Z'.

22. The compound of claim 21, wherein Y is A₂-DPro-A₄-A₅-Z'.

23. The compound of claims 1, 2 or 3, wherein Z' is -NH₂.

24. The compound of claim 3, selected from the group consisting of αAib-DTrp-DPro-A₄-A₅-A₆-Z', αAib-DTrp-DPro-A₄-A₅-Z', αAib-DTrp-DPro-A₄-Z', αAib-DTrp-DPro-A₄-Arg-NH₂, αAib-DTrp-DPro-A₄-Arg-A₆-NH₂, αAib-DTrp-DPro-A₄-Arg-Gly-NH₂, αAib-DαNal-DPro-A₄-A₅-A₆-Z', αAib-DαNal-DPro-A₄-A₅-Z', αAib-DαNal-DPro-A₄-Z', αAib-DαNal-DPro-A₄-NH₂, αAib-DαNal-DPro-A₄-Arg-NH₂, and αAib-DαNal-DPro-A₄-Arg-Gly-NH₂.

- 56 -

25. The compound of claim 24, wherein A₄ is Dlle, DThr, DNle, DVal, DGln, DAla, DPhe, DTrp, DNVal and Arg.

26. The compound of claim 1 which is selected from the group consisting of α AibDTrpDProDlleArgNH₂, α AibDTrpDProDThrArgNH₂, α AibDTrpDProDValArgNH₂, α AibDTrpDProDNleArgNH₂, and α AibD α NalDProDlleDArgNH₂.

27. The compound of claim 1, which is selected from the group consisting of α Aib-A₂-DPro-A₄-Z, α Aib-DTrp-DPro-DThr-NH₂, α Aib-DTrp-DPro-DGln-NH₂, α Aib-DTrp-DPro-Arg-NH₂, α Aib-DTrp-DPro-DAla-NH₂, α Aib-DTrp-DPro-DPhe-NH₂, α Aib-DTrp-DPro-DTrp-NH₂, α Aib-DTrp-DPro-DVal-NH₂, α Aib-DTrp-DPro-DNVal-NH₂, and α Aib-DTrp-DPro-Dlle-NH₂.

28. The compound of claim 1, which is selected from the group consisting of α Aib-DTrp-DPro-Dlle-Arg-Gly-NH₂, α Aib-DTrp-DPro-DThr-Arg-Gly-NH₂, and α Aib-DTrp-DPro-DNle-Arg-Gly-NH₂.

29. A compound selected from the group consisting of inipD α NalDTrpNH₂, inipD α NalDValNH₂, α AibDTrpDValNH₂, α AibDTrpDProDSerNH₂, α AibDTrpDProDArgNH₂, α AibDTrpDProDPheNH₂, α AibDTrpDProDTrpNH₂, α AibDTrpDValDValNH₂, α AibDValDProDValNH₂, α AibDValDValDValNH₂, α AibDTrpDProDLysNH₂, α AibDProDProDValNH₂, inipD α NalDTrpDValNH₂, α AibDTrpDProIleNH₂, α AbuD α NalDTrpDlleNH₂, inipD α NalDTrpDProIleNH₂, inipD α NalDTrpPheIleNH₂, inipD α NalDTrpDValArgNH₂, α AibDTrpDProDValDValNH₂, α AibDTrpDProDProDPalNH₂, α AibDTrpDProDValArgDProNH₂, α AibDTrpDProDlleDArgNH₂, α AbuDTrpDTrpDlleNH₂, inipD α NalDTrpPheDValNH₂, α AibDTrpDProValNH₂; α AibDTrpDlleDlleNH₂, α AibDTrpDProLeuNH₂, α AibDTrpDProThrNH₂, DHisDTrpDProDValArgNH₂, DHisDTrpDProDThrNH₂, α AibDTrpDProDlleNH₂, α AibDTrpDPheDValNH₂, α AibDTrpDProDValDArgNH₂, α AibDTrpDProDAlaNH₂, α AibDTrpDProDProNH₂, α AibDTrpDProArgNH₂, α AibDTrpDProDValNH₂, inipD α NalDTrpDProNH₂, α AibD α NalDProDValDArgNH₂, α AibD α NalDProDlleDArgNH₂, α AibDTrpDProDProDLysNH₂, α AibHisD α NalDPheLysNH₂, α AibHisDTrpDProDValNH₂, α AibHisDTrpDProDlleNH₂, α AibHisDTrpDProValArgNH₂,

α AibHisDTrpDProDValArgNH₂, α AibD α NalDProDValNH₂,
 α AibDTrpDProDThrArgNH₂, α AibDTrpDProDNleArgNH₂,
 α AibDTrpDProDNValArgNH₂, α AibDTrpDProIleArgNH₂,
 α AibDTrpDProDProArgNH₂, α AibDTrpDProProArgNH₂,
 α AibDTrpDProDProDArgNH₂, α AibDTrpDProDlleArgNH₂,
 α AibDTrpDProPheDSerNH₂, α AibDTrpDProPheArgNH₂,
 α AibDTrpDProDValArgNH₂, SarDTrpDTrpPheArgNH₂,
 α AibD α NalDProDProArgNH₂, α AibD α NalDProDNValArgNH₂,
 α AibD α NalDProDlleArgNH₂, α AibD α NalDProDValLysNH₂,
 α AibD α NalDProDThrArgNH₂, α AibD α NalDProDThrArgNH₂,
 α AibD α NalDProDValArgNH₂, α AibD α NalDProDValArgNH₂,
 α AibDTrpDProDNleNH₂, α AibDTrpDProDNValNH₂,
 α AibDTrpDProDProArgNH₂, α AibDTrpDProDValDArgNH₂,
 α AibDTrpDProDValArgNH₂, α AibDTrpDProDlleArgNH₂,
 α AibD α NalDProDValArgNH₂, α AibD α NalDProDValArgNH₂,
 α AibD α NalDProDlleArgNH₂, α AibD α NalDProDValLysNH₂,
inipD α NalD α NalPheArgNH₂, α AibDTrpDProDThrArgNH₂,
 α AibDTrpDProDNleArgNH₂, α AibDTrpDProDNValArgNH₂,
 α AibDTrpDProDlleArgGlyNH₂, α AibDTrpDProDProDlleArgGlyNH₂,
 α AibDTrpDProDNleArgGlyNH₂, α AibDTrpDProDThrArgGlyNH₂,
 α AibDTrpDProDProA₄ArgNH₂, α AibDTrpDProDProA₄ArgGlyNH₂,
 α AibDTrpDProDlleArgNH₂, α AibDTrpDProDlleArgGlyNH₂,
 α AibDTrpDProDProDlleArgNH₂, α AibDTrpDProDProDlleArgGlyNH₂,
D β NalAlaTrpDPheLysGlnGlyNH₂, DAlaDTrpAlaTrpDPheLysValGlyNH₂,
DAlaD β NalAlaTrpDPheLysGlnGlyGlyGlyNH₂, and
DAlaDTrpAlaTrpDPheLysHisGlyNH₂.

30. A compound of the formula A₁-A₂-X, wherein A₁ is Aib, inip or ABU; A₂ is any natural L-amino acid or Pal, or their respective D-isomers, D α Nal or D β Nal; and

X is (1) R₁-R₂-Z, wherein R₁ and R₂ are any natural L-amino acid, Pal, α Nal, β Nal, DpCl, CH_x, where CH_x is cyclohexyl, CH_xAla, or any of their respective D-isomers; and Z is CONH₂ or COOH;

- 58 -

- (2) $\text{DpR}_3\text{Phe-R}_4\text{-Z}$, wherein R_3 is a halogen; R_4 is L-amino acid or Pal, or their respective D-isomers; and Z is CONH_2 or COOH ;
- (3) $\text{NH}(\text{CH}_2)_n\text{NH}$, where n is 1 to 8;
- (4) $\text{R}_5\text{-R}_6$, wherein R_5 is any natural L-amino acid, Pal, αNal , βNal , DpCl , CH_x , or any of their respective D-isomers; and R_6 is diisobutylamide, dipropylamide, butylamide, pentylamide, dipentylamide, or $\text{C}(=\text{O})$ (substituted heteroalicyclic or heteroaromatic);
- (5) DTrp Phe ArgR_7 , wherein R_7 is $\text{NH}(\text{CH}_2)_n\text{NH}$, where n is 1 to 8; or
- (6) $\text{R}_8\text{-R}_9\text{-R}_{10}\text{-Z}$, wherein R_8 is DTrp, DPro, $\text{D}\alpha\text{Nal}$ or $\text{D}\beta\text{Nal}$; R_9 is any natural L-amino acid or Pal, or their respective D-isomers; R_{10} is any natural L-amino acid or Pal, or their respective D-isomers; and Z is CONH_2 or COOH .

31. A compound of the formula $\text{A}_1\text{-X}'$, wherein A_1 is Aib, inip, ABU, IMC, Ava, 4-IMA, βAla , Ileu, Trp, His, DpCl , CH_x where CH_x is cyclohexyl, or any of their respective D-isomers; and

X' is (1) $\text{R}_1\text{-R}_2\text{-Z}'$, wherein R_1 is any natural L-amino acid or Pal, or their respective D-isomers, $\text{D}\alpha\text{Nal}$ or $\text{D}\beta\text{Nal}$; and R_2 is any natural L-amino acid, Pal, αNal , βNal , DpCl , Aib, CH_x , or CH_xAla , or any of their respective D-isomers; and Z is CONH_2 or COOH ; or

(2) $\text{R}_3\text{-R}_4$, wherein R_3 is any natural L-amino acid or Pal, or their respective D-isomers, $\text{D}\alpha\text{Nal}$ or $\text{D}\beta\text{Nal}$; and R_4 is $\text{NH}(\text{CH}_2)_n\text{NH}$, where n is 1 to 8.

32. The compound of claim 30, wherein A_1 is αAib , and A_2 is selected from the group consisting of DTrp and $\text{D}\alpha\text{Nal}$.

33. The compound of claim 30, wherein A_1 is αAib ; A_2 is DTrp; X is $\text{R}_1\text{-R}_2\text{-Z}$, where R_1 is DPro, R_2 is selected from the group consisting of Gly, Phe, Pro, DPro, DPhe, DPal, DLeu, DHis, DVal, DGln, DArg, DAla, DSer, DThr and Dlleu, and Z is CONH_2 .

34. The compound of claim 30, wherein A_1 is $\alpha,\gamma\text{ABU}$ and A_2 is selected from the group consisting of DTrp and $\text{D}\alpha\text{Nal}$.

35. The compound of claim 34, wherein X is R_1-R_2-Z , where R_1 is DTrp, R_2 is selected from the group consisting of Arg, Lys and Orn, and Z is $CONH_2$.

36. The compound of claim 30, wherein A_1 is inip, A_2 is D α Nal and X is R_1-R_2-Z , where R_1 is DTrp, R_2 is selected from the group consisting of Phe, Pal, CH_x Val, Thr, Arg, Lys and Pro, and Z is $CONH_2$.

37. The compound of claim 30, wherein A_2 is DTrp, D α Nal or D β Nal; and

X is (1) R_5-R_6 , where R_5 is selected from the group consisting of DTrp and DPro; and R_6 is diisobutylamide, dipropylamide, butylamide, pentylamide, dipentylamide, or $C(=O)$ (substituted heteroalicyclic or heteroaromatic); or

(2) DTrp Phe Arg R_7 , wherein R_7 is $NH(CH_2)_nNH$, where n is 1 to 8.

38. The compound of claim 37, wherein R_6 is DPro- $C(=O)$ (substituted heteroalicyclic or heteroaromatic), wherein the heteroatom is selected from the group consisting of O, N, S and P.

39. The compound of claim 38, wherein the heteroalicyclic moiety contains 2 to 12 carbon atoms and the heteroaromatic moiety contains 5 to 12 carbon atoms.

40. The compound of claim 39, wherein the $C(=O)$ (substituted heteroalicyclic or heteroaromatic) moiety is selected from the group consisting of piperidine-3-methyl-benzylether, N-diethylnipectamide, N-piperazine methylsulfonamide, diethylamide, m-methylpiperidine, 3,3-diphenylpropylamide, 4-piperidino piperidinamide, 4-phenyl-piperidinamide, N-methyl 1-piperiazine, 2-morpholinoethylamine, spiroindole methylsulfonamide, pyrrolidine amide, indoleamide, 3-piperidine methanol amide, and tropin amide.

41. The compound of claim 37 wherein X is DPro NH_2 , DPro-diisobutylamide, DPro-butylamide, DPro- $C(=O)$ (substituted heteroalicyclic or heteroaromatic), or DTrp-Phe-Arg-5-aminopentamide.

42. The compound of claim 30, wherein X is $R_8-R_9-R_{10}-Z$, wherein R_8 is selected from the group consisting of DTrp or DPro; R_9 is selected from the group consisting of Phe or DVal; R_{10} is selected from the group consisting of Lys or Arg; and Z is $CONH_2$.

- 60 -

43. A method of promoting the release and elevation of blood growth hormone levels by administering the compound of claim 1, 2, 3, 30, 31 or 37 in a synergistic amount with a second compound, wherein the second compound is a compound which acts as an agonist at the growth hormone releasing hormone receptor or inhibits the release of somatostatin.

44. A pharmaceutical composition comprising the compound of claim 1, 30 or 37 and the pharmaceutically acceptable carrier or diluent.

45. The pharmaceutical composition of claim 44, which further comprises a second compound which acts as an agonist at the growth hormone releasing hormone receptor or inhibits the effects of somatostatin.

46. A method of promoting the release and elevation of blood hormone levels by administering the peptide of claim 1, 2, 3, 30 or 37 with at least a naturally occurring growth hormone releasing hormone and functional equivalents thereof, or a compound which promotes the release of growth hormone.

47. A method for treating hypothalamic pituitary dwarfism, osteoporosis or burns, which comprises administering a therapeutically effective amount of the peptide of claim 1, 30 or 31.

48. A method for promoting wound healing, promoting recovery from surgery or recovery from acute/chronic debilitating illnesses which comprises administering a therapeutically effective amount of the pharmaceutical composition of claim 44.

49. A method for prevention or reduction of cachexia in cancer patients which comprises providing a therapeutically effective amount of the compound of claim 1, 30 or 31.

50. A method for promoting anabolism and/or to prevent catabolism in humans which comprises administering a therapeutically effective amount of the compound of claim 1, 30 or 31.

51. The method of claim 50, wherein the therapeutically effective amount is about 30 μg to 1200 μg of the peptide per kg of body weight.

52. A method for increasing muscle in an animal and/or decreasing body fat which comprises administering an effective amount of the compound of claim 1, 30 or 31.

- 61 -

53. A method for improving serum lipid pattern in humans by decreasing in the serum the amount of serum cholesterol and low density lipoprotein and increasing in the serum the amount of the high density lipoprotein which comprises administering an effective amount of the compound of claim 1, 30 or 31.

54. The method of claim 52 wherein the effective amount ranges between about 0.1 μ g to 10 μ g of total peptide per kg of body weight.

55. The method of claim 53, wherein the effective amount ranges between about 0.1 μ g to 10 μ g to total peptide per kg of body weight.

56. A method for decreasing atherosclerosis which comprises administering an effective amount of the compound of claim 1, 30 or 31.

57. A method to improve cardiac performance in congestive heart failure and in patients with cardiac myopathy which comprises administering an effective amount of the compound of claim 1, 30 or 31.

58. A method to improve sleep which comprises administering an effective amount of the compound of claim 1, 30 or 31.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 February 2000 (24.02.2000)

PCT

(10) International Publication Number
WO 00/09537 A3

(51) International Patent Classification⁷: C07K 5/10, 7/06,
7/02, 5/02, A61K 38/07, 38/08, A61P 5/02, C07K 14/60

#816, 935 Loire Court, Peoria, IL 61614 (US); LIANG,
Yongwu [US/US]; 4607 Cypress Wood Drive, Spring, TX
77379 (US).

(21) International Application Number: PCT/US99/17867

(74) Agents: EISENSTEIN, Ronald, I. et al.; Nixon Peabody
LLP, 101 Federal Street, Boston, MA 02110 (US).

(22) International Filing Date: 6 August 1999 (06.08.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/096,795 14 August 1998 (14.08.1998) US
60/129,806 16 April 1999 (16.04.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US Not furnished (CIP)
Filed on Not furnished

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, UG, ZW); Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM); European patent (AT,
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE); OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): ADMIN-
ISTRATORS OF THE TULANE EDUCATIONAL
FUND [US/US]; Tulane University Medical Center,
School of Medicine, 1430 Tulane Avenue, New Orleans,
LA 70112-2699 (US).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BOWERS, Cyril,
Y. [US/US]; 484 Audubon Street, New Orleans, LA 70118
(US). MOMANY, Frank [US/US]; Versailles Hamlet

(88) Date of publication of the international search report:
20 September 2001

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY

(57) Abstract: Compounds that promote growth hormone releasing activity are disclosed. These compounds have the formula:
A₁-A₂-X; A₁-X*, or A₁-Y. These compounds can be present in a pharmaceutical composition. The compounds can be used with a
second compound that acts as an agonist at the growth hormone releasing hormone receptor or which inhibits the effects of somato-
statin. These compounds can be used for a variety of uses such as treating hypothalamic pituitary dwarfism, osteoporosis, burns, or
promoting wound healing.



WO 00/09537 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/17867

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K5/10 C07K7/06 C07K7/02 C07K5/02 A61K38/07
A61K38/08 A61P5/02 C07K14/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	R DEGHENGI: "Structural requirements of growth hormone secretagogues" GROWTH HORMONE SECRETAGOGUES IN CLINICAL PRACTICE. INTERNATIONAL SYMPOSIUM, XX, XX, 1997, pages 27-35, XP002118401	
A	DEGHENGI R ET AL: "SMALL PEPTIDES AS POTENT RELEASERS OF GROWTH HORMONE" JOURNAL OF PEDIATRIC ENDOCRINOLOGY AND METABOLISM, IL, FREUND PUBLISHING HOUSE, TEL AVIV, vol. 8, no. 4, 1 October 1995 (1995-10-01), pages 311-313, XP000651785 ISSN: 0334-018X	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

26 February 2001

Date of mailing of the international search report

07/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/US 99/17867

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DEGHENGHI R ET AL: "GH-RELEASING ACTIVITY OF HEXARELIN, A NEW GROWTH HORMONE RELEASING PEPTIDE, IN INFANT AND ADULT RATS" LIFE SCIENCES,GB,PERGAMON PRESS, OXFORD, vol. 54, no. 18, 1994, pages 1321-1328, XP000651534 ISSN: 0024-3205 ---	
A	WO 93 04081 A (UNIV TULANE) 4 March 1993 (1993-03-04) ---	
A	WO 94 07519 A (HUFFMAN WILLIAM FRANCIS ;MOORE MICHAEL LEE (US); SMITHKLINE BEECHA) 14 April 1994 (1994-04-14) ---	
A	US 5 776 901 A (COY DAVID ET AL) 7 July 1998 (1998-07-07) ---	
A	EP 0 083 864 A (BECKMAN INSTRUMENTS INC) 20 July 1983 (1983-07-20) -----	

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 17867

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-23,30-32,34,42-58 (all partially)

Present claims 1-23,30-32,34,42-58 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, a peptide sequence consisting virtually only of variables cannot be considered to be a clear and concise definition of patentable subject-matter (art. 6 PCT). The claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for all peptides listed in claims 24-29 and extended to those parts of the claims which appear to be adequately supported and disclosed, namely for claims 33 and 35-41, defining the peptide N-terminal portion.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/17867

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9304081 A	04-03-1993	US 5663146 A	02-09-1997
		WO 9220767 A	26-11-1992
		AT 172742 T	15-11-1998
		AU 666673 B	22-02-1996
		AU 2541692 A	16-03-1993
		BG 62655 B	28-04-2000
		BG 98489 A	28-02-1995
		BR 9206398 A	27-12-1994
		CA 2116120 A	23-02-1993
		CN 1073684 A, B	30-06-1993
		CZ 9400400 A	16-11-1994
		DE 69227462 D	03-12-1998
		DE 69227462 T	08-04-1999
		DK 605484 T	05-07-1999
		EP 0605484 A	13-07-1994
		ES 2124263 T	01-02-1999
		FI 940807 A	21-02-1994
		HU 69178 A	28-08-1995
		IL 102848 A	05-04-1998
		JP 7507039 T	03-08-1995
		KR 247212 B	15-03-2000
		MX 9204861 A	30-06-1994
		NO 940592 A	14-04-1994
		NZ 244034 A	28-08-1995
		PL 169562 B	30-08-1996
		RO 112507 B	30-10-1997
		RU 2126014 C	10-02-1999
		SK 20494 A	05-10-1994
		US 5776901 A	07-07-1998
		ZA 9206337 A	22-04-1993
WO 9407519 A	14-04-1994	EP 0663834 A	26-07-1995
		JP 8502250 T	12-03-1996
US 5776901 A	07-07-1998	US 5663146 A	02-09-1997
		CN 1073684 A, B	30-06-1993
		MX 9204861 A	30-06-1994
		NZ 244034 A	28-08-1995
		AT 172742 T	15-11-1998
		AU 666673 B	22-02-1996
		AU 2541692 A	16-03-1993
		BG 62655 B	28-04-2000
		BG 98489 A	28-02-1995
		BR 9206398 A	27-12-1994
		CA 2116120 A	23-02-1993
		CZ 9400400 A	16-11-1994
		DE 69227462 D	03-12-1998
		DE 69227462 T	08-04-1999
		DK 605484 T	05-07-1999
		EP 0605484 A	13-07-1994
		ES 2124263 T	01-02-1999
		FI 940807 A	21-02-1994
		HU 69178 A	28-08-1995
		IL 102848 A	05-04-1998
		JP 7507039 T	03-08-1995
		KR 247212 B	15-03-2000
		NO 940592 A	14-04-1994
		PL 169562 B	30-08-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/17867

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5776901 A		RO 112507 B	30-10-1997
		RU 2126014 C	10-02-1999
		SK 20494 A	05-10-1994
		WO 9304081 A	04-03-1993
		ZA 9206337 A	22-04-1993
EP 0083864 A	20-07-1983	US 4410512 A	18-10-1983
		US 4410513 A	18-10-1983
		US 4411890 A	25-10-1983
		AU 549053 B	09-01-1986
		BR 8208035 A	22-11-1983
		CA 1242435 A	27-09-1988
		CA 1317069 A	27-04-1993
		DE 3276319 D	19-06-1987
		DK 114192 A	16-09-1992
		DK 390883 A	26-08-1983
		FI 833057 A, B,	26-08-1983
		IE 54515 B	08-11-1989
		IL 67577 A	31-07-1988
		IL 82215 A	31-07-1988
		KR 8902760 B	27-07-1989
		KR 9002681 B	23-04-1990
		NZ 218384 A	06-01-1989
		PH 27490 A	23-07-1993
		PT 76041 A, B	01-01-1983
		WO 8302272 A	07-07-1983
		ZA 8209519 A	26-10-1983
		PH 21326 A	13-10-1987
		MX 9203562 A	01-09-1992